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ABSTRACT
1. The classification of adenosine receptors has been summarised and the involvement 
of these receptors in the cardiovascular system has been described.
2. Adenosine and its analogues induced relaxations of the rat isolated thoracic aorta 
and the rat coronary arteries. The agonist potency orders indicate the presence of A2 
receptors although the high potency of the A2  ^ selective agonist CGS 21680 suggests 
that these relaxations were mediated via A2  ^ receptors. However, as the maximal 
responses to CGS 21680 in the rat thoracic aorta was only 6 6 % of the NEC A maximal 
response, it is possible that CGS 21680 was acting as a partial agonist on the A2  ^
receptors present on this tissue.
3. On the rat thoracic aorta, the endogenous nucleoside MTA was a very weak agonist 
but its effects were not inhibited by the non selective antagonist 8 -SPT. This suggests 
that the relaxations induced by this agonist were not mediated by the A2  ^receptors on 
the aorta but by another site which is resistant to blockade by 8 -SPT. However, MTA 
also appears to act as an antagonist on the A2  ^receptors on the rat aorta inhibiting the 
relaxations induced by the adenosine agonists with a potency similar to that of 8 -SPT.
4. In the rat thoracic aorta, MTA, the non selective antagonist 8 -SPT and the A2 a 
selective antagonist PD 115,199 inhibited the relaxations induced by the adenosine 
agonists. However, NECA was inhibited to a greater extent than the other agonists by 
these antagonists. This suggests that all of these agonists, vvith the exception of MTA, 
were acting on the A2 a receptors present on the aorta. It also suggests that CGS 
21680, CPA, adenosine and APNEA may not be acting solely on this receptor. It is 
possible that these agonists were also acting on another site on the aorta which 
displays some resistance to blockade by these antagonists, hence the lesser degree of
antagonism. This site may be the same xanthine-resistant site on the aorta at which 
MTA acts as a weak agonist.
5. Aj receptors are unlikely to be present on the rat thoracic aorta as an Aj selective 
concentration of DPCPX (InM) did not inhibit the relaxations induced by APNEA, 
adenosine and CPA. The dififering degrees of antagonism of the agonist responses by 
8 -SPT and MTA and the xanthine-resistant relaxant effects of MTA do not appear to 
involve A3 receptors as the agonist potency order produced in the presence of these 
antagonists was different to the potency order which would be expected if A3 
receptors were present.
6 . Initially, when studying the adenosine receptors in the rat coronary arteries using the 
Langendorff isolated heart technique, the concentration response curves for the 
adenosine agonists in the presence and absence of antagonists and L-NAME were 
carried out in separate hearts. However, interpretation of the increases in flow induced 
by the agonists became difiScult due to other effects, such as decreases in basal flow, 
which were produced by the inhibitors. Therefore the effect of the inhibitors on the 
basal flow and the increases in flow induced by SNP and NECA were then investigated 
in a paired fashion in each heart. It was found that these inhibitors caused a decrease 
in the basal flow through the heart indicating vasoconstriction of the coronary vessels. 
This vasoconstriction lead to physiological/functional antagonism of the agonist 
induced responses causing a reduction in the vasodilation obtained. The results 
obtained with the agonist concentration response curves were subsequently 
reinterpreted in the light of this complication.
7. In the rat isolated heart, 8 -SPT inhibited the increase in flow induced by the 
adenosine agonists confirming the involvement of the Pj receptors in this response and 
also suggesting that A3 receptors are not involved in mediating coronary vasodilation.
8 , In the rat coronary arteries, the A2 a selective antagonist PD 115,199 inhibited the 
increase in flow induced by NECA and CGS 21680. Whilst the concentration response 
curve produced by NECA was shifted to the right by PD 115,199 (30nM), a lower 
concentration of PD 115,199 (lOnM) virtually abolished the concentration response 
curve produced by CGS 21680. Initially this suggested that both of these agonists act 
via the A2 g receptors on this tissue although the different degrees of antagonism by PD 
115,199 could not be explained. However, it was later found that PD 115,199 caused 
vasoconstriction of the coronary vessels which led to physiological/functional 
antagonism of the agonist responses and therefore a reduction in the vasodilations 
induced by the agonists. When taking this physiological antagonism into 
consideration, the concentration response curves for NECA in the presence and 
absence of PD 115,199 were very similar, suggesting that, in fact, PD 115,199 had no 
effect on the NECA induced responses. Therefore NECA was probably not acting via 
the A2 a receptors but possibly via A215 receptors to produce vasodilatation of the 
coronary arteries.
9. Mechanical removal of the endothelium from the rat isolated aorta, or incubation of 
the intact aorta with the nitric oxide synthase inhibitor L-NAME (30pM), virtually 
abolished the relaxations induced by the adenosine agonists. This indicates that these 
responses are endothelium-dependent and are mediated via the nitric oxide pathway. 
Initially in the rat isolated heart, the presence of L-NAME inhibited the concentration 
response curves for NECA and CGS 21680 shifting the curves to the right, whilst 
abolishing the responses to CPA and adenosine, although this was due to their low 
potency in the absence of the inhibitor. This would imply that in the coronary arteries 
the agonist induced vasodilations are partially endothelium-dependent and are 
mediated via the endothelium and the vascular smooth muscle. However, it was found 
that L-NAME caused vasoconstriction of the coronary vessels, which led to 
physiological antagonism of the agonist responses and therefore a reduction in the 
vasodilations induced by the agonists. When this physiological antagonism was taken
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into consideration the concentration response curves of the agonists in the presence 
and absence of L-NAME were very similar indicating that L-NAME had no effect on 
the increases in flow induced by the agonists. This suggests that, unlike the rat 
thoracic aorta, the vasodilation induced by the adenosine agonists in the coronary 
arteries is endothelium-independent and does not involve the nitric oxide pathway.
1 0 . As well as decreasing the basal flow through the heart and reducing the increases in 
flow induced by the agonists, L-NAME also decreased the force of contraction of the 
heart. SNP however, not only increased the force but also increased the rate of 
contraction of the heart although it had no effect on the isolated atria. These effects of 
L-NAME and SNP were probably not direct effects but consequences of the changes 
in vessel tone and subsequent changes in the flow rate induced by L-NAME and SNP. 
A decrease or increase in the flow rate would lead to an insufficient or greater 
perfiision of the heart respectively and consequently this would alter the hearts' ability 
to contract.
11. In conclusion, the relaxations of the rat thoracic aorta induced by the adenosine 
agonists are mediated via A2 a receptors and by another site on the aorta which displays 
resistance to blockade by 8 -SPT, MTA and PD 115,199. The agonist responses were 
abolished by endothelium removal and inhibition by the nitric oxide synthase inhibitor 
L-NAME and therefore they were endothelium-dependent and were mediated via the 
nitric oxide pathway. In the rat coronary arteries, the adenosine agonists caused 
increases in flow through the heart indicating vasodilation of the vessel. Inhibitors 
such as L-NAME, 8 -SPT and PD 115,199 caused vasoconstriction of the coronary 
vessels, indicated by a decrease in the basal flow through the heart, which led to 
physiological antagonism of the agonist induced vasodilations. This physiological 
antagonism and a time dependent reduction in the agonist responses were taken into 
consideration when interpretation of the agonist responses in the isolated heart were 
carried out. The vasodilations induced by the agonists were mediated by A2 receptors
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although the high potency of the A2  ^ selective agonist CGS 21680 would suggest that 
these receptors are of the A2 a receptor subtype. However, the increase in flow 
induced by NECA was not inhibited by PD 115,199 suggesting that NECA is acting 
via A2b receptors to mediate coronary vasodilation. The increases in flow induced by 
the agonists were not inhibited by L-NAME indicating that they were endothelium- 
independent and therefore mediated via receptors present on the vascular smooth 
muscle of the coronary arteries.
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CHAPTER 1: 
INTRODUCTION
1.1. HISTORICAL BACKGROUND
In 1929, an extract of ox heart was shown to produce physiological effects on the 
cardiovascular system when injected into intact animals (Drury and Szent-Gyorgi, 
1929). It was demonstrated that adenosine and adenylic acid (AMP, adenosine 5'- 
monophosphate) isolated from these extracts, could modify the cardiovascular system 
by inducing bradycardia and heart block, reducing the contractility of the atria and 
decreasing the arterial blood pressure, which was, in part, due to arterial dilation 
(Drury and Szent-Gyorgi, 1929). This was the first indication that physiological 
systems could be modulated by purines such as adenosine.
Little interest was shown in these findings until 1963 when Berne proposed that 
adenosine was involved in the metabolic regulation of coronary blood flow (Berne, 
1963). When myocardial oxygen levels are low, for example during hypoxia and 
ischaemia, high concentrations of inosine and hypoxanthine, metabolites of adenosine, 
are measured in the blood. Berne proposed that adenosine released from the 
myocardium was involved in a feedback mechanism to restore the myocardial oxygen 
levels by causing arteriolar dilation and an increase in coronary blood flow (Berne, 
1963).
It was not until 1970 that evidence was produced to suggest that adenosine modulated 
physiological functions by acting at specific receptors. Sattin and Rail (1970) 
demonstrated adenosine induced accumulation of cAMP in brain slices and the 
inhibition of this effect by the presence of a methylxanthine, theophylline. This was the 
first evidence to suggest that this effect of methylxanthines was due to antagonism of 
adenosine receptors rather than phosphodiesterase inhibition, as previously thought 
(Sattin and Rail, 1970).
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Following these initial findings, the actions of adenosine on physiological systems other 
than the cardiovascular system has been investigated, and fiirther characterisation of 
the adenosine receptors has been carried out.
1.2. PRODUCTION AND METABOLISM OF ADENOSINE
There are two main pathways for the production of adenosine: i) hydrolysis of adenine 
nucleotides, ii) hydrolysis of S-adenosylhomocysteine.
Intracellular dephosphorylation of adenosine 5'-triphosphate (ATP) to adenosine 5- 
diphosphate (ADP), ADP to AMP and AMP to adenosine are catalysed by the 
cytosolic enzymes adenosine triphosphatase, myokinase and 5'-nucleotidase 
respectively (Pearson and Slakey, 1990; Schütz et al., 1981, Figure 1). This process 
can also occur extracellularly catalysed by ectonucleotidases present on the outer 
surface of the plasma membrane of vascular endothelial cells (Fleetwood et ah, 1989; 
Schrader et a l, 1990). The second source of adenosine is S-adenosylhomocysteine 
(SAH) which is derived fi'om its parent compound S-adenosylhomomethionine (SAM) 
when SAM is utilised in transmethylation reactions. SAH undergoes enzymatic 
hydrolysis by SAH hydrolase to produce adenosine and homocysteine (De La Haba 
and Cantoni, 1959; Schrader et al., 1981, Figure 1). It is now understood that due to 
the relative activities of the enzymes SAH hydrolase and 5’-nucleotidase the 
production of adenosine through these pathways is balanced. The SAH pathway is 
more dominant during normoxia when the activity of 5’-nucleotidase is very low and 
the hydrolysis of 5'AMP becomes more important during hypoxia when 5’- 
nucleotidase activity increases greatly whilst the activity of SAH hydrolase only 
increases by 1.5 fold (Lloyd and Schrader, 1987). Adenosine can be metabolised to 
inosine and hypoxanthine by adenosine deaminase and xanthine oxidase which occur
13
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Figure 1. Schematic diagram of the production and metabolism of adenosine
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both as intracellular and extracellular enzymes. Alternatively, phosphorylation of 
adenosine by cytosolic adenosine kinase can regenerate 5'-AMP (Figure 1).
Adenosine can be transported across the cell membrane by carrier mediated facilitated 
diffusion (Oliver and Paterson, 1971). The carrier is able to transport nucleosides 
other than adenosine across the membrane which subsequently can become 
competitive inhibitors of adenosine transport. Some inhibitors of adenosine transport / 
uptake have been synthesised including dipyridamole, 6 -S-(p-nitrobenzyl- 
thio)guanosine (NBTGR) and 6 -S-(p-nitrobenzylthio)inosine (NBTI) (Paterson and 
Oliver, 1971; Cass et al., 1974). Clinically dipyridamole has been used as a coronary 
vasodilator mainly based on its action of adenosine uptake inhibition. The production 
and metabolism of adenosine are described in greater detail in reviews by Olsson and 
Pearson (1990) and Pearson and Slakey (1990).
1.3. CLASSIFICATION OF PURINOCEPTORS
Purinoceptors are cell surface receptors which can associate with, and may have their 
actions modified by purines such as adenosine and its related analogues. The 
classification of receptors such as purinoceptors have been carried out in a variety of 
ways including observation of biological effects, association with individual second 
messenger systems, radioligand binding and molecular biology techniques, but mainly 
through agonist and antagonist potency orders and structure activity relationships 
established for each of the receptors (Kenakin et al., 1992).
In 1978, Bumstock proposed that purinoceptors could be subdivided into 2 main 
groups based on the potency order of adenosine and adenine nucleotides, sensitivity to 
xanthine antagonists, modification of adenylate cyclase activity and stimulation of 
prostaglandin synthesis. Pi purinoceptors are more sensitive to adenosine than ATP 
producing a potency order of adenosine > AMP > ADP > ATP. Agonists acting at
15
these receptors cause the inhibition or stimulation of adenylate cyclase and this effect 
can be antagonised by methylxanthines. purinoceptors however, have the reverse 
potency order, ATP > ADP > AMP > adenosine and the effects of agonists are not 
antagonised by methylxanthines but may lead to stimulation of prostaglandin synthesis 
(Bumstock, 1978).
1.3.1. Pj purinoceptors
Pi purinoceptors have been further classified into Ai and A% purinoceptors. Van 
Calker et al. (1979) reported that in cultured brain cells adenosine acted by either 
inhibiting or stimulating adenylate cyclase via A \ and A% receptors respectively. An 
alternative nomenclature was used by Londos et al. (1980) to classify observations 
seen in adipocytes and hepatocytes. Inhibition of adenylate cyclase was denoted by Ri 
whilst activation of adenylate cyclase was denoted by Ra, the R signifying that an intact 
ribose moiety was required for the modulation of adenylate cyclase activity. However, 
it has since been shown that adenosine receptors can bind to effector systems other 
than adenylate cyclase so for this reason the A1/A2  nomenclature has now been 
adopted as it does not imply modulation of a specific second messenger system. 
Further classification of the adenosine receptors has been carried out with an A3 
purinoceptor in atrial tissue and on presynaptic sites of frog neurones being proposed 
by Ribeiro and Sebastiao (1986). However, this receptor has not been widely 
accepted. Another A3 receptor was proposed in 1992 by Zhou et a l based on the 
cloning and functional characterisation of a receptor fi-om the rat striatum (Zhou et a l, 
1992). This receptor has been cloned from other species such as the sheep and human 
(Linden et a l, 1993b; Salvatore et a l, 1993) as well as functional characterisation of 
A3 receptors in cultured rat mast cells (Ramkumar et a l, 1993).
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1.3.1,1. A l receptors
In the central nervous system adenosine acts via pre synaptic Aj receptors to inhibit 
the release of neurotransmitters such as noradrenaline, 5HT, dopamine, acetylcholine 
and GABA (Stone, 1981; Harms et a l, 1978; Williams, 1984). In the periphery A% 
receptors also occur post junctionally mediating cardiac depression (Collis, 1983), 
smooth muscle contraction (Bailey et al., 1992), vasoconstriction (Stoggall and Shaw, 
1990) and bronchoconstriction (Farmer et ah, 1988), inhibition of renin secretion 
(Murray and Churchill, 1984) and inhibition of lipolysis (Londos et al., 1980). From 
the original classification of the adenosine receptors, adenosine acting via Aj receptors 
inhibit adenylate cyclase activity (Van Calker et a l, 1979; Londos et a l, 1980). 
However, it is now known that A  ^receptors can couple to second messenger systems 
other than adenylate cyclase for example, activation of potassium channels (Belardinelli 
et a l, 1988), inhibition of phospholipase A2  and calcium channels (Schimmel and 
Elliot, 1988; Ribeiro and Sebastiao, 1986), stimulation of guanylate cyclase (Kurtz, 
1987) and the activation and inhibition of phospholipase C (Hill and Kendall, 1987; 
Petcoff and Cooper, 1987).
Currently the principal method of classification of Pi purinoceptors is by determination 
of the potency orders of agonists and antagonists and possible structure activity 
relationships (SAR). The adenosine structure can be modified in a variety of ways to 
produce analogues of differing selectivity and potency for the adenosine receptors. Ai 
receptors are preferentially activated by adenosine analogues substituted at the 
position of the adenine moiety, for example N^-cyclopentyladenosine (CPA) and N^- 
cyclohexyladenosine (CHA) (Bruns et a l, 1986). N^-(phenylisopropyl)adenosine 
(PIA) can be created by substituting the phenylisopropyl stereoisomers of 
amphetamine at the position of adenosine to produce R- and S- isomers of PIA, 
both of which are useful in classification of the purinoceptors due to the high potency 
of R-PIA and the 10 to 100 fold stereoselective preference for R-PIA over S-PIA at
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the Aj receptors (Collis, 1983; Bumstock and Buckley, 1985). A potency order for 
various adenosine analogues at the Aj receptor can be seen in Table 1, where CPA is 
the most potent and selective Aj agonist (Kj = 0.59nM, 784 and 407 fold selectivity 
for the Aj receptor versus A2 a and A3 receptors respectively, Bmns et ah, 1986; Van 
Galen et al., 1994). The stmcture of some adenosine agonists can be seen in Figure 2.
L3.1.2. A2 receptors
A2  receptors occur post junctionally mediating relaxation of smooth muscle
CvJivN R/)
(Bumstock et ah, 1984;|NichoUs et al., 1992)f vasorelaxation (Rose’meyer and Hope, 
/  ^
/(  1990; Martin, 1992)i bronchorelaxation (Brown and Collis, 1982) and inhibition of 
platelet aggregation (Dionisotti et al., 1992).
Although modification of the ribose moiety of adenosine is not well tolerated by the 
purinoceptors, substitution at the 5' position appears to be an exception. For example, 
one such analogue, 5'-(N-ethylcarboxamido)adenosine (NECA) has a high potency at 
A2  receptors and moderate potency at Aj receptors, and although it is ofl:en used as an 
A2  selective agonist it is actually non selective for all the Pj purinoceptor subtypes 
(Bmns et ah, 1986; Van Galen et ah, 1994, for stmcture see Figure 2). N^ substituted 
adenosine analogues such as CPA and R-PIA have little activity at this receptor, 
although an exception is N^-[2-(3,5-dimethyloxyphenyl)-2-(2-methylphenyl)ethyl] 
adenosine (DPMA) which is a potent A2  agonist, and the stereoisomer R-PIA is only 
1-10 times more potent than S-PIA at the A2 receptor (Bridges et a l, 1988; Brown 
and Collis, 1982; Bumstock and Buckley, 1985). Substitution at the C2 position of 
the adenine moiety can increase the potency of adenosine analogues for the A2  
receptor. Increasing the size of this substituent to include cyclic and longer chain 
stmctures creates analogues such as 2-phenylaminoadenosine (CV 1808) and 2 -[p- 
(carbonylethyl)phenylethylamino)-5'-(N-carboxamido)adenosine (CGS 21680) which
18
Figure 2. Structures of some adenosine receptor agonists
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have been shown to be potent and selective agonists (CGS 21680 Kj = 15nM, 140 
and 39 fold selective for the A%a receptor versus A% and A3 receptors respectively, 
Bruns et a l, 1986; Hutchinson et a l, 1989; Van Galen et a l, 1994). A potency order 
for various adenosine analogues at the A2  receptor can be seen in Table 1, and the 
structure of some of these analogues can be seen in Figure 2.
1.3.1.3. Â2 receptor suhtypes
The A2  receptor was subdivided by Daly et a l  (1983) into A2 a and A2b receptors 
according to a difference in affinity for adenosine receptor analogues. A high affinity 
binding site (A2 a) for adenosine was reported in the rat striatal membrane (in the 
presence of an A% selective agonist CPA to preclude binding) whilst a low affinity 
site (A2b) was reported on intact brain cells and human fibroblasts (Daly et al., 1983; 
Bruns et a l, 1986; Bruns, 1980a). Agonists acting through both receptor subtypes 
stimulate adenylate cyclase, but it was proposed that A2 a receptors were responsible 
for activation of adenylate cyclase in striatal homogenates whilst stimulation of the A2b 
receptors may elevate general cAMP levels in the brain and brain slices. Using ligand 
potency orders it appears that the A2 a receptor has a relatively higher affinity for 
agonists and a relatively lower affinity for antagonists than the A2b receptor (Bruns et 
a l, 1986). Although there are no selective agonists for the A2b receptor, NECA has a 
high potency, 2-chloroadenosine (2-CADO) moderate potency, and the N^ substituted 
analogues low potency at this receptor (Table 1). Agonists with bulky C2  position 
substituents i.e. CV 1808 and CGS 21680 have a very low affinity for the A2b receptor 
and a high affinity for the A2 a receptor, for example, in the guinea-pig aorta (which 
contains A2b receptors) CGS 21680 has a p[A5o] of 3.61 whilst in the guinea-pig 
langendorff heart preparation (containing A2a receptors) a p[A5o] of 9.13 was 
produced (Martin, 1992; Ueeda et a l, 1991a). As CGS 21680 binding and activation 
of adenylate cyclase occurs mainly in the striatum, CGS 21680 is
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considered to be an A2 a selective agonist and is often used to distinguish between the 
A%a and A2b receptor subtypes (Jarvis et al., 1989; Hutchinson et a l, 1989). The 
physiological and functional relevance of this receptor division is not yet known but 
may become clearer with the use of selective agonists and antagonists to distinguish 
between the receptors on various tissues and correlate them to the functional effects 
observed.
L 3.1.4. As receptors
A third receptor subtype has been proposed by Ribeiro and Sebastiao (1986), although 
this subtype has not been widely accepted. Based on a review of the existing literature 
they called this receptor, the A3 receptor. They observed that in atrial tissue and at 
presynaptic sites in peripheral and central neurones, especially in the frog, purines 
exhibit an agonist potency order which does not fit the general K\l A2  receptor 
classification. At A% receptors, substituted analogues such as R-PIA have a 
greater potency than 5' substituted analogues such as NECA, at A2  receptors NECA 
has a greater potency than R-PIA, but at these putative A3 receptors, the analogues 
appear to be equipotent. Ribeiro and Sebastiao (1986) also proposed that this receptor 
may not be linked to adenylate cyclase but to calcium channels and may be involved in 
the inhibition of calcium influx or mobilisation. Kennedy et aï. (1992a) measured the 
relative potencies of several adenosine agonists mediating inhibition of lipolysis in the 
rat adipocyte (A% mediated response), inhibition of neuronally mediated contraction of 
the guinea-pig ilieum (proposed A3 mediated response) and negative chronotropic and 
inotropic effects in the guinea-pig and rat atria (proposed A3 mediated response). It 
was found that the rank order of agonists was the same in all of these preparations 
(CPA > CHA = R-PIA > NECA > S-PIA) and that the agonists had similar potencies 
relative to NECA over all the tissues, suggesting that the receptors in the ilieum and 
atria, which were proposed to be A3 receptors, are identical to the Ai receptors in the
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adipocytes. It is known that A% receptors can couple with second messenger systems 
other than adenylate cyclase so different agonist potency orders and effector systems 
does not preclude this proposed A3 receptor from being of the A% subtype.
Recently, Zhou et al. (1992) reported the cloning and functional characterisation of a 
receptor from the rat striatum which has also been called the A3 receptor, although this , 
receptor is different to that proposed by Ribeiro and Sebastiao (1986). This receptor 
is expressed in high levels in the testes and lower levels in the lung, kidneys, heart and 
the cortex, striatum and olfactory bulb of the central nervous system (Zhou et al.,
1992). Agonists such as R-PIA, NECA and the A  ^ selective agonist N^-2-(4-amino-3- 
phenyl)-ethyladenosine (APNEA) have high potencies at this receptor with a 6 -fold 
enantiomeric preference for R-PIA versus S-PIA (Zhou et a l, 1992; Van Galen et a l,
1994). Further development of A3 agonists has produced N^-benzyl substituted 
analogues such as N^-benzyl-5’-(N-ethylcarboxamido)adenosine (Benzyl-NECA) 
which has a 13 and 14 fold selectivity for the A3 receptor versus the Aj and A2  ^
receptors respectively, and N^-(iodobenzyl)-5’-(N-methylcarboxamido)adenosine (IB- 
MECA) which is also a very selective (50 fold) A3 agonist (Gallo-Rodriguez et a l,
1994; Van Galen et a l, 1994). Substitution at the C2 position of this analogue 
produces another analogue 2-chloro- N^-(iodobenzyl)-5’-(N-methylcarboxamido) 
adenosine (2-Cl-IB-MECA) which is the most potent and selective A3 receptor agonist 
to date displaying a Kj of 0.33nM in binding in transfected CHO cells using [l^^I]-AB- 
MECA (N^-[1^^I]- 4-amino-3-(iodobenzyl)-5’-(N-methylcarboxamido) adenosine) and 
is selective for the A3 receptor versus the A% and A2  receptors by 2500 and 1400 fold 
respectively (Kim et a l, 1994a). The rat A3 receptor appears to be insensitive to the 
classical xanthine antagonists such as 8 -p-(sulphophenyl)theophylline (8 -SPT), DPCPX 
and xanthine amine congener (8-{4-[({[(2-aminoethyl)amino]carbonyl}methyl)oxy]- 
phenyl}-1,3-dipropylxanthine, XAC) (Zhou et a l, 1992). This receptor was found to 
be identical to a receptor clone called tgpcrl previously cloned from a rat testes cDNA 
library (Meyerhof et a l, 1991). Further A3 receptors have been cloned from a sheep
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pars tuberalis cDNA library and human striatum (Linden et a l, 1993b; Salvatore et a l,
1993). However, the tissue distribution of these receptors differs from that of the rat 
A3 receptor in that they are more widespread. In the sheep high levels were expressed 
in the lung, spleen, pars tuberalis and pineal gland, and moderate levels in the testes, 
kidney and brain, whilst in the human high levels of the A3 receptor are expressed in 
the lung and Hver, moderate levels in the brain and aorta, and low levels in the testes 
and heart (Linden et a l, 1993b; Salvatore et a l, 1993). Whilst the agonist potencies 
for the sheep and human A3 receptors remain the same as for the rat A3 receptor, both 
of these receptors can bind DPCPX and XAC with low affinity, and also have the 
ability to bind some acidic substituted 8 -phenykanthines such as 3-(-iodo-4- 
aminobenzyl)-8-(4-oxyacetate)-1 -propylxanthine (BW-A522, I-ABOPX) with 
nanomolar affinity (Linden et a l, 1993b). The rat, sheep and human A3 receptors have 
been shown to inhibit forskolin stimulated cAMP production in Chinese Hamster ovary 
(CHO) cells (Zhou e/ a l, 1992; Linden et a l, 1993b; Salvatore et a l, 1993). 
Recently, Ramkumar et a l (1993) reported the presence of A3 receptors on cultured 
mast cells (RBL-2HL). This receptor has the same binding profile (R-PIA = NECA > 
S-PIA) as the cloned A3 receptor fi’om the rat striatum as well as the low sensitivity to 
xanthine antagonists. Activation of this cloned receptor stimulates a transient 
production of inositol 1,4,5-triphosphate leading to a transient increase in the 
intracellular calcium levels. Functionally this results in potentiation of the secretory 
response to antigens in the mast cells (Ramkumar et a l, 1993). Studies carried out in 
the angiotensin-n supported circulation of the pithed rat indicated that a decrease in 
blood pressure induced by adenosine agonists including APNEA are resistant to 
blockade by xanthine antagonists such as 8 -SPT and DPCPX (Fozard and Carruthers, 
1993a; Carruthers and Fozard, 1992; 1993). This was attributed to the activation of 
A3 receptors within the cardiovascular system which mediate hypotension. However, 
it was found that the hypotensive response induced by APNEA could be inhibited by 
the mast cell stablising agent sodium cromoglycate and was decreased after repeated 
doses of the mast call degranulating agent compound 48/80. Therefore it was
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concluded that A3 receptor mediated, APNEA induced hypotension was due to the 
activation of A3 receptors present on the mast cells (Hannon et al., 1995). Further 
evidence to support the involvement of A3 receptors was found using BW-A522 (I- 
ABOPX) to block the hypotensive response of APNEA in pithed rats, although the 
potency of BW-A522 as an antagonist is lower at the rat A3 receptor than at the sheep 
or human A3 receptors (Fozard and Hannon, 1994). It appears that the properties of 
this cloned receptor are distinct from those of the A% and A2  subtypes. Continued 
emergence of functional roles for the A3 receptor will further strengthen the 
classification of this receptor.
i. 3,1.5. receptors
An A4  receptor has been recently proposed by Cornfield et al. (1992) based on a 
unique agonist potency order of CV 1808 > CGS 22988 »  NECA > CGS 21680 for 
[^H] CV 1808 competition binding in the rat striatum at 4°C. However, it has since 
been shown that if binding is carried out at 21°C then the agonist potency order 
becomes characteristic of an A2  ^receptor (Luthin and Linden, 1995). It would appear 
that the A4  receptor is a temperature sensitive form of the A2  ^ receptor producing a 
different potency order at 4°C because CGS 21680 loses its affinity to the A2 a receptor 
at this temperature (Luthin and Linden, 1995).
1.3.2. The P site
In vitro, high concentrations of adenosine (mM) inhibit the activation of adenylate 
cyclase via the P site (Londos and WolfiF, 1977). This appears to be an intracellular 
site on the catalytic subunit of adenylate cyclase which requires a purine moiety for 
modulation, hence the term P site. Agonists include adenosine, 2-CADO and 2', 5'- 
dideoxyadenosine but the 5'- and N^- substituted analogues NECA, 5'-N-cyclopropyl- 
carboxamidoadenosine (CCPA), R-PIA and CHA are not agonists (Daly, 1982). The
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p site is not susceptible to blockade by xanthines such as 8 -SPT but its activation in 
intact cells can be attenuated by adenosine transport inhibitors such as dipyridamole 
(Collis and Brown, 1983). Since high concentrations of adenosine are required to 
activate this site it is unlikely that it is physiologically significant and therefore is 
referred to as a site rather than a receptor.
1.3.3. Adenosine receptor antagonists
In 1970 Sattin and Rail demonstrated that the naturally occurring xanthines caffeine 
and theophylline blocked the adenosine stimulated accumulation of cAMP in brain 
slices. This was the first evidence to show that although xanthines can act as 
phosphodiesterase inhibitors their main action is considered to be antagonism of 
adenosine effects (Choi et a l, 1988). Caffeine and theophylline are non selective for 
the A \ and A2  receptor but attempts have been made to produce more selective and 
potent antagonists based on the xanthine structure. Bruns (1980b) suggested that 
xanthine antagonists act at the same site as the adenosine agonists but probably in a 
different orientation. In 1986 Bruns et al. developed this suggestion further by noting 
that the 5 membered ring of the xanthine lies in an equivalent position to the 6  
membered ring of the adenosine structure in the purinoceptor (Bruns et al., 1986). 
Based on the observation that at the Aj receptor the structure activity relationships for 
substituted adenosine agonists were similar to those obtained for the 8 -substituted 
xanthine antagonists, Peet et al. (1990) suggested the " N^-C8 " model where the 
and C8  positions of the agonists and antagonists occupy the same binding pocket in the 
A% receptor.
Substitution at the 8 -position of the xanthine structure with a wide range of chemical 
groups increases the potency of the adenosine antagonists considerably, as shown by 
the increase in potency of 8 -phenyltheophylline (8 -PT) from theophylline, however this 
analogue has poor water solubility which has limited its use (Bruns and Fergus, 1989).
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The addition of a sulphur group to produce 8 -SPT increases the water solubility of the 
analogue but as with 8 -PT this compound appears to be non-selective for A \  and A2  
receptors (Collis et a l, 1987).
1.3.3.1, AI receptor antagonists
Further development of 8 -substituted xanthines produced antagonists with some Ai 
selectivity, for example DPCPX has been shown to have a consistent and marked 
selectivity for the A \ receptor in a range of preparations and species. In the guinea-pig 
atria, which contains A% receptors, and the guinea-pig aorta, which contains A2  
receptors, the non-selective antagonist 8 -SPT produces pA2  values of 4.9 and 5.0 
respectively (Collis et a l, 1989). These are significantly different to the pA2  values 
produced by DPCPX in these tissues. In the guinea-pig atria, DPCPX produces a pA2  
value of 7.9 whereas in the guinea-pig aorta a pA2  value of 6 . 6  has been shown, hence 
DPCPX can be used to differentiate between A% and A2  receptors (Collis et a l, 1989). 
The structure of some xanthine antagonists can be seen in Figure 3 a.
1.3.3.2. A2  receptor antagonists
There are several non-xanthine analogues such as the triazoloquinazoline CP 66713 
and the triazoloquinoxaline CGS 15943 which show some selectivity for the A2 a 
receptor (Nikodijevic et a l, 1991; Ghai et a l, 1987). However, due to limited 
selectivity for the A i  receptor versus the A \ receptor (approximately 7 fold for CGS 
15943), poor water solubility and the possibility that CGS 15943 may act non 
competitively at some A2 a receptors, these antagonists are not used routinely 
(Williams et a l, 1987a). Another non-xanthine antagonist that has recently been 
described is ZM241385 (4-(2-[7-amino-2-(2-furyl)[l,2,4]triazolo[2,3-a][l,3,5]triazin- 
5-yl)amino]ethyl)phenol). This analogue displays a high affinity for the A2 a receptor 
(pA2  of 8.57) and appears to be the most selective A2 a receptor antagonist with
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selectivities of 400-1000 fold, 30-80 fold and 6700 fold for the A \, A2 b and A3  
receptors respectively (Poucher et al., 1995). The structures of CGS 15943 and 
ZM241385 can be seen in Figure 3b. The xanthine analogue PD 115,199 (N-[2- 
(dimethylamino)ethyl]-N-methyl-4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3 -dipropyl-1H- 
purin-8 -yl)benzene sulphonamide) has been reported to have equal affinity at the A \ 
and A2 a receptors in binding studies in the rat striatum producing Kj values of 13.9 
and 15.5 nM respectively (Bruns et al., 1987). It has been also reported that PD 
15,199 binds to the high affinity (A2 a) sites in the striatum whilst no binding was 
observed at the low affinity (A2 b) sites, suggesting that this compound is selective for 
the A2 a receptor versus the A2 b receptor but can not distinguish between the A2 a and 
A% receptors (Bruns et al., 1987). This is fiirther supported by the finding that in the 
dog saphenous vein and guinea-pig aorta, which contain A2 b receptors, PD 115,199 
has a low affinity (ED3 0  of 151 and 275 nM respectively) compared to the high affinity 
at the A2 a receptors in binding to the rat striatal membranes (IC5 0  of 16nM) 
(Hargreaves et al., 1991; Jarvis et al., 1989). Recently it has been reported that the 
introduction of 8 -styryl groups in the xanthine structure increases the potency and 
selectivity of the antagonists for the A2 a receptor (Shimada et a l, 1992; Jacobson et 
a l, 1993). One such compound, KF 1737 ((E)-1,1 -dipropyl-7-methyl-8-(3,4- 
dimethoxystyryl)xanthine) has been shown to be a highly selective A2 a antagonist both 
in vitro and in vivo, although this antagonist may have limited use due to its rapid 
photoisomerisation when diluted in dimethylsulphoxide (DMSG) and exposed to light 
(Jackson et a l, 1993; Nonaka et a l, 1994). CSC (8-(3-chlorostyryl)caffeine) is 
another 8 -styryl substituted compound which has a 520 fold selectivity for the A2 a 
receptor versus the A \ receptor in binding studies in the rat brain but only 22 fold 
selectivity for the A2 a receptor in functional studies in rat pheochromocytoma (PC 12) 
cells (Jacobson et a l, 1993).
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Figure 3. Structure of some xanthine and non-xanthine adenosine antagonists
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1.3.3,3. receptor antagonists
The rat A3  receptor was originally classified by its insensitivity to classical xanthine 
antagonists such as 8 -SPT, DPCPX and XAC but some acidic substituted 8 - 
phenylxanthines such as BW-A522 (I-ABOPX) and BW-A1433 have been shown to 
be more effective antagonists at the A3  receptor (Zhou et a l, 1992; Linden et a l, 
1993b). Kim et a l (1994b) have recently produced afidnity values in the micromolar 
range for some antagonists at the rat A3  receptor producing an antagonist order of 
BW-A522 (I-ABOPX) > DPCPX > BW-A1433 > XAC »  CSC, where BW-A522 is 
the most effective antagonist with an afiinity of 1.17pM whilst CSC was inactive (Kim 
et a l, 1994b). In the rat, BW-A522 was 32 and 2 fold more selective for the A \ and 
A2 a receptors versus the A3  receptor whilst BW-A1433 was 1000 fold and 19 fold 
more selective for the A% and A2 a receptors versus the A3  receptor, therefore both of 
these analogues are not selective for the rat A3  receptor (Kim et ah, 1994b). BW- 
A522 and BW-A1433 are more potent at the sheep and human A3  receptors than at 
the rat A3  receptor producing affinities of 3nM and 21nM in the sheep and 18nM and 
55nM in the human respectively (Linden et a l, 1993b; Salvatore et a l, 1993). The 
antagonist potency order produced in the sheep and human was BW-A522 > BW- 
A1433 > XAC »  DPCPX (Linden et a l, 1993b; Salvatore et a l, 1993). The structure 
of I-ABOPX (BW-A522) can be seen in Figure 3 a.
1.3.4. Molecular biology studies
In recent years molecular biology techniques have provided another approach to the 
study of adenosine receptors and their structure and distribution, although by their 
nature these studies focus mainly on the structural properties of the purinoceptors 
rather than their functional aspects. The division of adenosine purinoceptors on a
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pharmacological basis into Ai, A2  and A3  subtypes has now been supported by 
evidence produced using molecular biology techniques.
1.3.4.1. AI receptors
In 1989, Libert et al. began the interest in the cloning of adenosine receptors by 
cloning two orphan receptors, RDC7 and RDC8  from a canine cDNA library whilst 
screening for sequences homologous to transmembrane sections of other G protein- 
coupled receptors (Libert et a l, 1989). Libert et a/. (1991) went on to identify RDC7 
as the A \ receptor based on the distribution of the RDC7 transcript in the cortex, 
hippocampus, thyroid gland and testes using in situ hybridisation, and functional data 
such as rank order of agonist affinities in radioligand binding and inhibition of forskolin 
stimulated cAMP production (Libert et a l, 1991; 1992). The A] receptor has also 
been cloned from several other species, for example, Reppert et al. (1991) and Mahan 
et a/. (1991) have cloned a rat A \ receptor which has 91% homology to the canine A \ 
receptor. The bovine A \ receptor has greater than 90% homology to the rat and 
canine A \ receptors but displays a different agonist potency order of R-PIA > S-PIA > 
NECA compared to the "classical" A \ receptor potency order of R-PIA > NECA > S- 
PIA found in the rat and dog (Tucker et a l, 1992; Olah et a l, 1992; Linden et al, 
1993a). Libert et al. (1992) also described the cloning of a human A \ receptor from a 
hippocampus cDNA hbrary, whilst Salvatore et al. (1992) cloned a human A \ receptor 
from ventricle, brain and kidney cDNA libraries. This clone encodes a protein of 326 
amino acids in length and is 94% homologous to the canine, rat and bovine A \ 
receptors (Salvatore e ta l, 1992; Jacobson, 1995).
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1.3.4.2. A 2a receptors
The striatal distribution of RDC8 , binding of [3r]NECA and [3h]CGS 21680 in COS- 
7 cells and the activation of adenylate cyclase when RDC8  is expressed in transfected 
cells such as Xenopus oocytes led to RDC8  being identified as the A%a receptor 
(SchifiBnann et al., 1990; Maenhaut et al., 1990). A rat A2 a receptor was identified 
by Chem et al. (1992) and Fink et al. (1992) which was 82% homologous to the 
canine A2 a receptor (RDC8 ). Using in situ hybridisation Fink et al. (1992) also 
showed that the A2 a adenosine receptor was co-expressed in the same striatal neurons 
as the dopamine D2  receptors, but not the D\ receptors indicating a possible reason 
for the interaction between these two receptor systems in the control of some motor 
functions (Jarvis and Williams, 1987). The human A2 a receptor has been cloned fi'om 
a hippocampal cDNA library and a heart ventricle and striatal cDNA library (Furlong 
et al., 1992; Salvatore et al., 1992). This clone encodes a protein of 412 amino acids 
with 93% homology to the canine RDC8  receptor but only 84% homology to the rat 
A2 a receptor (Jacobson, 1995).
1.3.4.3. A2J) receptor
A protein (RFL9) has been cloned from the rat brain which has 45% and 46% 
homology with A \ and A2 a adenosine receptors respectively, although RFL9 has a 
different distribution to the Aj and A2 a receptors as it is found in high levels in the 
large intestine, caecum and bladder. (Stehle et a l, 1992). Transfection of C0S-6M 
cells with RFL9 resulted in the binding of NECA with high affinity, but not the A] and 
A2 a selective agonists CCPA and CGS 21680 and also NECA stimulated the 
production of cAMP whereas CGS 21680 did not (Stehle et a l, 1992). These 
properties would suggest that this protein is an A2 b receptor. Further evidence was 
provided by the finding that in Chinese hamster ovary (CHO) cells transfected with
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RFL9 the stimulation of cAMP production by adenosine agonists and their inhibition 
by the adenosine antagonists correlated highly with the responses seen in the human 
VA13 fibroblasts which have been shown to contain A2 b receptors (Rivkees and 
Reppert, 1992; Bruns et al., 1986). The human A2 b receptor was cloned by Pierce et 
al. (1992) from a hippocampal cDNA library. This clone encodes a protein of 328 
amino acids in length with 8 6 % homology to the rat A2 t> receptor and 45% homology 
to the human A% and A2 a receptors (Pierce et al., 1992). When the hippocampus 
clone was expressed in CHO cells similar pharmacological properties to the rat A2 b 
receptor were seen with respect to agonist binding and stimulation of cAMP 
production (Pierce et al., 1992).
I.3.4.4. receptor
This receptor was originally identified by molecular biology cloning techniques rather 
than by pharmacological fianctional studies. Meyerhof et al. (1991) cloned an orphan 
receptor tgpcrl fi-om a rat testes cDNA library which had 47% and 42% homology to 
the RDC7 and RDC8  receptors respectively. In 1992, Zhou et al. cloned an identical 
protein (R226) fi'om the rat striatum with 58% homology to the A \ and A2  receptors 
vrithin the transmembrane regions of the receptors, and this has subsequently been 
called the A3  receptor (Zhou et al., 1992). The A3  receptor has also been cloned from 
a sheep pars tuberalis cDNA library (SI7) obtaining 72 % homology to the rat A3  
receptor and fi'om a human striatal cDNA library (HS-21a) with a sequence that has 
72% homology to the rat A3  receptor and 85% homology to the sheep A3  receptor 
(Linden et al., 1993b; Salvatore et al., 1993). As mentioned previously there is a 
difference in the distribution and affinity of xanthine antagonists between the rat and 
the sheep and human A3  receptors. This difference can also be seen in the receptor 
sequences with a higher similarity (85%) between the sheep and human A3  receptors 
compared to 74% between the rat A3  receptor and the sheep and human A3  receptors. 
Another human clone (pl2H) has been produced from a heart cDNA library using the
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rat A3  sequence, although this receptor only has 71% homology to the rat A3 receptor 
(Sajjadi and Firestein, 1993). The proteins that these clones encode vary slightly in 
length, for example, the rat A3  receptor is 320 amino acids in length, the sheep A3 
receptor is 317 amino acids in length and the human striatal and heart A3  receptors are 
318 and 319 amino acids respectively in length (Zhou et al., 1992; Linden et al., 
1993b; Salvatore a/., 1993; Sajjadi and Firestein, 1993).
1.4. ACTIONS OF ADENOSINE ON THE CARDIOVASCULAR SYSTEM
Adenosine and its analogues have been shown to modulate the fimctions of several 
physiological systems including the cardiovascular, respiratory, gastrointestinal, central 
nervous system and immunological systems. The actions of adenosine in the 
cardiovascular system will be reviewed here but its actions on other systems are 
described elsewhere in reviews by Jacobson, (1990) and Collis and Hourani, (1993).
1.4.1. Al receptor
Adenosine has negative dromotropic, chronotropic and inotropic actions on the heart. 
Adenosine acts on the atrioventricular (AY) and sinoatrial (SA) nodes to cause a 
decrease in the impulse conduction time through the AY node (heart block) and a 
decrease in the pacemaker firing rate (bradycardia). Based on the agonist potency 
order of CPA > R-PIA > NECA > 2-CADO it would appear that both of these effects 
are due to the activation of A% receptors and also probably involve an increase in 
potassium conductance (Clemo and Belardinelli, 1986; Belardinelli etal., 1988; Evans 
et al., 1982). Adenosine also acts on the atria to produce negative inotropic effects. 
The decrease in force of contraction caused by adenosine is again mediated via the Aj 
receptor and involves a decrease in the action potential and an increase in the 
potassium conductance (Evans et al., 1982; Collis, 1983; Belardinelli and Isenberg, 
1983a; Jahwel and Nawath, 1989). Adenosine has little direct effect on the
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contractility of the ventricular myocardium, however it has an indirect effect by 
antagonising the positive inotropic effects of catecholamines. This anti-adrenergic 
effect is achieved by the inhibition of the increase in cAMP and the slow inward 
calcium current induced by the catecholamines (Belardinelli and Isenberg, 1983b)
1.4.2. A% receptor
Adenosine and its analogues induce vasodilation in a variety of blood vessels within the 
cardiovascular system (Table 2). Agonist potency orders such as NECA > R-PIA> 2- 
CADO > adenosine suggests that A% purinoceptors mediate vasodilation in vascular 
tissues (Kusachi et al., 1983; King et al., 1990). Recently with the use of the A2 a 
selective agonist CGS 21680 some of the A2  receptors found on vascular tissues have 
been further subdivided into A2 a or A2b receptors. For example, the A2  receptors on 
the dog coronary artery have been classified as A2 a receptors (Gurden and Kennedy, 
1992; Kennedy et al., 1992b), whilst those on the guinea-pig aorta have been classified 
as A2b receptors (Losinski et al., 1993; Hargreaves et al., 1991) due to the respective 
high and low potency of CGS 21680 on these tissues. Further studies with xanthine 
antagonists have also supported the proposal that A2  receptors mediate vasodilation. 
For example, a pA2  value of 6 . 6  was reported in the guinea-pig aorta using DPCPX 
indicating that vasodilation in this tissue was mediated by A2  receptors (Collis et al.,
1989), whilst Losinski et al. (1993) reported that PD 115,199 (an A2 a selective 
antagonist) had a low affinity on this tissue confirming that the purinoceptor present 
was probably of the A2b subtype.
Until recently the location of the A2  receptor was assumed to be on the vascular 
smooth muscle with vasodilation achieved by direct action on these purinoceptors, for 
example, endothelium independent vasodilations were seen in tissues such as guinea- 
pig aorta, rat femoral artery, rabbit mesenteric artery and pig coronary artery (Collis 
and Brown, 1983; Kennedy et al., 1985; Mathieson and Burnstock, 1985; King et al.,
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1990). However, there are examples where adenosine acts on A2  receptors on the 
endothelium where its effects can be abolished or attenuated by the removal of the 
endothelium by mechanical means (Gordon and Martin, 1983; Kennedy and Burnstock, 
1985; Rubanyl and Vanhoutte, 1985). Liang (1992) put forward a working model 
suggesting that under basal conditions when endogenous adenosine concentrations are 
low, vasodilation is induced via the endothelial A2  receptors producing endothelium 
dependent vasodilation. During hypoxia when large concentrations of adenosine are 
produced, it is possible that adenosine can pass through the endothelium and act on the 
vascular smooth muscle A2  receptors inducing vasodilation by both endothelium 
dependent and independent means.
The mechanism of action of endothelium dependent relaxation is thought to involve the 
release of Endothelium Derived Relaxing Factor (EDRF) from the endothelium. Due 
to similar biological and chemical properties of EDRF and nitric oxide (NO), it has 
been concluded that EDRF and NO are identical (Palmer et a l, 1987; 1988; Ignarro et 
a l, 1987). NO is synthesised by the conversion of L-arginine to L-citrulline by an 
enzyme called NO synthase and although many isoforms of this enzyme exist, the 
isoform present in the endothelial cells is a soluble, constitutive form which is regulated 
by calcium/calmodulin and requires NADPH as a cofactor (Palmer et a l, 1988; Palmer 
and Moncada, 1989). Another isoform of nitric oxide synthase is also present on the 
vascular smooth muscle cells. This is a calcium independent inducible form which is 
induced by bacterial products and cytokines but also requires NADPH as a cofactor 
(for review see Moncada et a l, 1991). Research into the involvement of NO in the 
relaxation of vascular smooth muscle has benefited from the production of NO 
synthase inhibitors. Analogues of arginine such as N^-monomethyl-L-arginine (L- 
NMMA) and N^-L-arginine methyl ester (L-NAME) are competitive stereospecifrc 
inhibitors of NO synthase, although the inhibition can be reversed by the addition of 
arginine (Rees etal., 1989; 1990)
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Table 2. The classification and endothelium dependency of adenosine receptors in the
peripheral arteries of a variety of species
ARTERY and RECEPTOR ENDOTHELIUM REFERENCE
SPECIES DEPENDENCY
C o r o n a r y  a r t e r y
Rat Pi - Fleetwood & Gordon (1987)
^ 2 - Hamilton et al., (1987)
^ 2 - Oei et al., (1988)
^ 2 a - Hutchinson et al., (1989)
Guinea-pig Pi Independent Keef et al, (1992)
A2 (A2 a) Partial Vials & Burnstock (1993)
A2 - Martin et al, (1993),
Canine Pi Independent White & Angus (1987)
A2 ' Kusachi gr a/., (1983)
A2 a - Gurden & Kennedy (1992)
A2 a - Kennedy et a l, (1992b)
A2 a - Croning et a l, (1992)
Human A2 Independent Sabouni e ta l , (1990)
A2 - Ramagopal et a l, (1988)
A2 a - Makujina et a l, (1992)
Porcine A2 Independent King e ta l , (1990)
A2 Independent Makujina et a l, (1993)
A2 (A2 a) Partial Abebe et al, (1994)
A2 (A2 a) - Balwierczak et a l,{ \99 \)
Bovine A2 - Cushing et a l, {\99\)
A2 - Mustafa & Askar (1985)
A2 (A2 a) - Conti et al, (1993)
Rabbit A2 - Odwara et a l, (1986)
A o r t a
Rat A2
A2 (A2 a)
A2 (A2 a)
Dependent
Dependent
Partial
Rose'meyer & Hope (1990) 
Moritoki et a l, (1990) 
Conti et a l, (1993)
Yen et a l, (1988)
Guinea-pig A2
A2
A2 (A2 b)
A2 b
A2b
A2 b
A2 b
A2b
A2 b
A2 b
Partial
Independent
Stoggall & Shaw (1990) 
Headrick & Berne (1990) 
Collis & Brown (1983) 
Martin (1992)
Alexander et a l, (1994) 
Gurden & Kennedy (1992) 
Hargreaves et a l,{ \99 \)  
Kennedy et a l, (1992b) 
Losinski et al, (1993) 
Martin et a l, (1993)
Rabbit A2 - Ghia & Mustafa (1982)
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Table 2. (Continued)
ARTERY and RECEPTOR ENDOTHELIUM REFERENCE
SPECIES DEPENDENCY
F e m o r a l  a r t e r y
Rat Pi Independent Kennedy et al., (1985)
Rabbit Al Independent Cassis et a l, (1987)
Canine - Independent De Mey & Vanhoute (1981)
M e s e n t e r ic  A r t e r y
Rat Pi Partial Vuorinen et a l, (1992)
A2b Independent Rubino et al., (1995)
Rabbit - Independent Mathieson & Burnstock (1985)
H e p a t ic  A r t e r y
Rabbit Pi
A2 (A2 a)
Independent Brizzolara & Burnstock (1991) 
Mathie et a l,{ \99 \)
C e n t r a l  e a r  A r t e r y
Rabbit Pi Partial Kennedy & Burnstock (1985)
R e n a l  A r t e r y
Rat A2 b Dependent Martin & Potts (1994)
P u l m o n a r y  A r t e r y
Rabbit A2 Partial Steinhom et a l, (1994)
Human A2 Independent McCormack et al., (1989)
Lamb Pi - Konduri et al., (1992)
The classification and endothelium dependency of adenosine receptors in a selection 
of peripheral arteries in a variety of species. Receptor subtype in parenthesis indicates 
the possible subtype of A2  receptor that could be implied by the potency of A2 a 
selective agonists such as CGS 21680 and CV 1808 although this receptor subtype 
was not stated explicitly by the authors.
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EDRF is believed to relax vascular smooth muscle by activating soluble guanylate 
cyclase, therefore increasing levels of cyclic guanosine monophosphate (cGMP) within 
the vascular smooth muscle (Rapoport and Murad, 1983; Waldman and Murad 1987; 
Ignarro, 1989). The mechanism for cGMP induced relaxation has not been fully 
elucidated. However, one such possible mechanism is the activation of cGMP 
dependent protein kinase, and a modification of the phosphorylation of various smooth 
muscle proteins for example, the dephosphorylation of myosin light chain has been 
associated with vasorelaxation (Rapoport et ah, 1993). Alternative suggestions for the 
mechanism of cGMP induced relaxation include decreasing the fi-ee cytosolic calcium 
concentration by the inhibition of phospholipase C and therefore inositol phosphate 
production, stimulation of Ca^-ATPase and the opening of potassium channels and the 
inhibition of calcium influx (Rapoport, 1986; for review see Lincoln, 1989).
Originally, Van Calker et al. (1979) classified A% receptors based on stimulation of 
adenylate cyclase by purines. This would suggest that the stimulation of endothelial A% 
receptors would increase cAMP. Indeed, Graier et al. (1992) reported that in pig 
aortic endothelial cells adenosine amplified bradykinin and ATP induced biosynthesis 
of EDRF via an increase in cAMP, cAMP dependent phosphorylation and an increase 
in the intracellular calcium concentration. Also in cultured guinea-pig coronary 
endothelial cells, purines enhanced the cAMP accumulation with a potency order of 
NECA > R-PIA and adenosine indicating the presence of A2  receptors (Des Rosiers 
and Nees, 1987). However there are examples where an increase in cAMP is not 
associated with vasorelaxation due to the stimulation of receptors. For example, in 
the porcine coronary arteries, Herlihy et al. (1976) reported that there was no increase 
in cAMP at the adenosine agonist concentrations that induced vasorelaxation via the 
stimulation of A2  receptors, whilst Cassis et al. (1987) reported that in the rabbit 
femoral artery a transient increase in cAMP was seen prior to, but not during 
vasorelaxation. Classification of purinoceptors as an A2  subtype however should not 
preclude it from being associated with second messenger systems other than adenylate
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cyclase. For example, Moritoki et al. (1990) proposed that release of EDRF, 
stimulation of guanylate cyclase and an increase in cGMP, rather than cAMP, mediates 
vasodilation induced by adenosine via endothelial receptors on the rat thoracic aorta. 
GrifiBth et al. (1985) also indicated that cGMP was involved in the endothelium 
dependent relaxation of the rabbit aorta. For this reason classification of A2 receptors 
on vascular tissues is based on agonist and antagonist potency orders rather than 
modulation of second messenger systems.
Although the main action of adenosine on blood vessels is vasodilation via 
receptors, in the kidney adenosine not only induces vasodilation of the afferent and 
efferent arterioles via the stimulation of A2  receptors, it also induces vasoconstriction 
of the afferent arterioles via stimulation of A  ^ receptors (Churchill and Churchill, 
1985; Murray and Churchill, 1984). This vasoconstriction leads to a decrease in renal 
blood flow and glomerular filtration rate and hence a decrease in energy demand as less 
solute needs to be reabsorbed into the kidney. This is fiirther evidence for the 
hypothesis that adenosine acts as a 'retaliatory metabolite’ (Murray and Churchill, 
1984; Berne, 1963; Newby, 1984). Stimulation of A2  receptors by adenosine induces 
an increase in renin secretion, whilst the activation of Aj receptors causes an inhibition 
of renin secretion (Churchill and Churchill, 1985). Further details of the effects of 
adenosine in the kidney can be found in the review by Spielman and Arend (1991).
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1.5. AIM OF THE THESIS
Adenosine has been shown to mediate vasodilation of many blood vessels in a variety 
of species via the activation of adenosine receptors. The aim of the thesis was to study 
the ?! purinoceptors present on blood vessels such as the thoracic aorta and the 
coronary arteries of the rat to characterise the purinoceptor subtype present and 
investigate other properties of the receptors, for example, to determine whether the 
adenosine receptors were present on the endothelium or on the vascular smooth 
muscle.
The isolated rat thoracic aorta was chosen as an example of a large diameter artery 
whilst the rat coronary arteries, studied using the Langendorff isolated heart 
preparation, were chosen as an example of small diameter arteries. In both of these 
cases adenosine has been shown to produce vasodilation of the vessels indicating the 
presence of adenosine receptors, so consequently further investigation of these 
receptors can be undertaken (Rose’meyer and Hope, 1990; Fleetwood and Gordon, 
1987). The identity of the adenosine receptor subtype mediating the vasodilation of 
the thoracic aorta and the coronary arteries of the rat was investigated using a range of 
adenosine agonists and antagonists such as NECA, CGS 21680, 8 -SPT, PD 115,199 
and DPCPX.
The location of the purinoceptors within the blood vessels was also investigated by 
ascertaining whether the presence of endothelium was required for receptor mediated 
vasodilation. This could be achieved by inhibition of nitric oxide synthesis using nitric 
oxide synthase inhibitors such as L-NAME, or in the case of the thoracic aorta, also by 
mechanical denudation of the vessel.
41
CHAPTER 2: 
METHODS
2.1. PHARMACOLOGICAL METHODS
2.1.1. Rat isolated thoracic aorta
Male Wistar rats (200-250g) obtained from the University of Surrey breeding unit 
were killed by cervical dislocation. The thoracic cavity was opened up and the 
thoracic aorta dissected out. The aorta was cleaned of connective tissue and a 6 mm 
ring was cut from the central portion of the aorta. One ring was obtained from each 
aorta. The rings were mounted on 6 mm stainless steel hooks in 4ml organ baths 
containing modified Krebs Henseleit solution (mM: NaCl, 118; KCl, 4.7; NaHCOg, 25; 
glucose, 11; MgS0 4 .7 H2 0 , 0.45; KH2 PO4 , 1.2; EDTA, 0.03; CaCl2 .2 H2 0 , 2.5), 
maintained at 37°C and aerated with 95% O2  : 5% CO2  The tissues were equilibrated 
for 1 hour at a resting tension of 2.5g with isometric responses subsequently recorded 
with a Grass FT03 force displacement transducer and displayed on a Grass polygraph 
(model 79).
A noradrenaline (NA) concentration response curve was obtained to ascertain a 
submaximal concentration of NA for contraction of the aortic rings (Figure 4). 
Subsequently the aortae were contracted three times with noradrenaline (lOOnM) to 
produce a stable contraction. The integrity of the aortic endothelium was assessed by 
the addition of acetylcholine (ACh, IpM) and those tissues showing less than 65% 
relaxation to ACh were discarded. The endothelium was deliberately removed from 
some aortae by gently rubbing the luminal surface with a metal rod and absence of the 
endothelium was confirmed by the failure of ACh (IpM) to induce relaxations. To 
measure the relaxant effects of the agonists the tissues were incubated with 
noradrenaline (lOOnM) for 3-4 minutes until a stable plateau was reached before the 
addition of the agonists. Responses were expressed as % inhibition of the NA-induced 
contraction. All the agonist concentration response curves were constructed non 
cumulatively, with a random order of agonist concentrations and a 2 0  minute
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Figure 4. Concentration response curve for NA in 
the rat thoracic aorta.
3 -1
2.5-
2 -
II
0.5-
10 100 10000.1 1
NA Concentration (nM)
Contraction of the intact rat thoracic aorta induced by 
noradrenaline. Each point represents the mean of at least 4 
determinations with s.e. mean shown as vertical bars.
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ECgo values can be defined as the concentration of the agonist producing 30% inhibition of 
the NA contraction.
PÀ2  can also be defined as the logarithm of the (dose-ratio -1) minus the logarithm of the 
molar concentration of the antagonist i.e. PÂ2  = log (dr-1) - log[A].
wash-out time between doses of noradrenaline. To study the effects of 8 -SPT, PD 
115,199, DPCPX, MTA and N^-nitro-L-arginine methyl ester (L-NAME) the tissues 
were equilibrated with these compounds for a period of 2 0  minutes prior to the 
addition of noradrenaline. Only one concentration response curve was carried out on 
each tissue due to the length of time (approamately 7 hours) required to construct one 
curve. y
pECgo values (the negative logarithm of the EC3 0  value) were calculated from the 
linear portion of individual log. concentration response curves by linear regression 
analysis. Potency of the agonists was expressed as EC3 0  values calculated from the 
mean of the PEC3 0  values. For the antagonists, the dose-ratios were calculated as the 
ratio of the EC3 0  values in the presence and absence of one concentration of the 
antagonist and estimated pA% values were calculated as the negative logarithm of the ) 
(molar concentration of the antagonists divided by the dose-ratio
2.1.2. Langendorff isolated rat heart preparation
Initial attempts to use a Langendorff isolated heart preparation involved using a 
‘constant-flow’ system where the perfusion flow through the heart was held constant 
and a change in perfusion pressure, measured by a Statham P23ID pressure transducer 
gave an indication of the vasodilation induced by the adenosine agonists. The 
equipment used was similar to that described later in the ‘constant-pressure’ system, 
except the Krebs Henseleit solution was supplied to the junction box above the heart 
via a Harvard peristaltic pump and a heating coil. One reason why the ‘constant-flow’ 
system was discarded was the very small changes in pressure induced by the adenosine 
agonists. The size of these changes made reliable measurements of responses very 
difficult, and would have made the use of antagonists impractical. It is possible that 
the pressure changes were small due to the dampening of the responses by a irbubbles 
in the equipment and the overriding pulsatile flow produced by the peristaltic pump
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which was detected by the pressure transducer. Due to the many problems that arose 
with the ‘constant-flow’ system it was decided to convert this equipment to a 
‘constant-pressure’ isolated heart system which was then used for the rest of this study 
and has been described below.
Male Wistar rats (280-3 80g) obtained from the University of Surrey breeding unit 
were injected with 500 Units heparin i.v. via the tail vein 5 minutes prior to being 
killed by cervical dislocation. The heart was rapidly excised from the thoracic cavity 
and plunged into ice cold Krebs Henseleit solution (mM; NaCl, 118; KCl, 4.7; 
NaHCOs, 25; glucose, 11; MgS0 4 .7 H2 0 , 1.17; KH2PO4 , 1.2; CaCl2 .2 H2 0 , 2.5). The 
heart was subsequently mounted on a cannula via the ascending aorta and the cannula 
suspended from the junction box while excess lung and connective tissue were 
removed (see Figure 5 for diagram of equipment). The heart was perfused with the 
Krebs Henseleit solution at a temperature of 37°C (measured at the junction box at the 
point of entry to the cannula) and aerated with 95% 0% : 5% CO2 from a reservoir 
which was at a height of Im above the heart. The perfusion of the heart was 
maintained at a constant pressure of 75mmHg which was continuously measured by a 
Statham P23ID pressure transducer connected to the junction box immediately above 
the cannulated aorta. A Harvard Minipuls pump was used to replenish the Krebs 
Henseleit solution within the reservoir to maintain the required pressure. A heart clip 
was attached to the apex of the heart and the heart was then left to equilibrate for 2 0  
minutes under a tension of 3g with isometric responses subsequently recorded with a 
Grass FT03 force displacement transducer to measure the force of contraction of the 
heart. This signal was integrated by a Grass tachograph to produce a measurement of 
the heart rate. To constrain the heart to a constant rate, silver plated needle electrodes 
were placed on the apex of the heart close to the heart clip and on the right ventricle 
near to the right atrium and the heart was stimulated using a Grass S48 stimulator with 
parameters of 5 volts, 2ms delay and a frequency of 4Hz to produce a heart rate of 240
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Figures. Schematic diagram of the isolated heart equipment
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beats/minute. The pressure, force and rate measurements were displayed on a Grass 
polygraph (model 79).
All the agonists were infused into the heart, using a Harvard variable speed infusion 
pump via a rubber septum in the junction box, at a rate which was 1 / 1 0 0 th of the basal 
perfusion flow (control flow) through the heart. The coronary flow was measured 
volumetrically by collecting the coronary effluent in a tared beaker beneath the heart. 
In initial experiments the basal perfiision flow (control flow) through the heart was 
calculated as the mean of 3 consecutive 30 second measurements of the flow. NEC A, 
over a range of concentrations, was infused into the heart at 1/ 1 0 0 th of this flow rate 
and flow measurements were taken over 30 second intervals from 0 to 4 minutes 
(Figure 6 a). To determine whether the increase in flow induced by the NECA had 
reached a plateau during this time, flow measurements of three concentrations of 
NECA (final concentrations, 0.3pM, 3pM, 30pM) were taken over 30 second 
intervals from 0 to 12 minutes (Fig 6 b). From this it was decided to simplify the 
protocol. Taking into account the different initial velocities of the flow increases and 
the different plateaux reached by the curves, it was decided to measure the control 
flow over 0 to 5 minutes followed by a 0 to 5 minute measurement of flow whilst the 
agonists were being infiised (agonist flow), and a 5-10 minute washout time between 
agonist concentrations. At the start of every experiment a dose of sodium nitroprusside 
(SNP) (lOOpM) was infiised into the heart to check its viability. If the increase in flow 
induced by SNP was less than Iml/min the heart was discarded. Where inhibitors or 
antagonists were used the first agonist applied to the heart after their equilibration was 
also SNP (lOOpM).
Initially, the results were expressed as the percentage increase in the flow induced by 
the agonists relative to the control flow (% Control flow (mls/min)). However, due to 
the decrease in the basal perfusion flow (control flow) throughout the experiment and 
the finding that this flow was sometimes influenced by the previous agonist response,
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Figure 6. Increase in flow induced bv NECA in the rat
isolated heart
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Increase in Flow in the rat isolated heart induced by NECA (O) 0.1 jiM, 
(■) 0.3pM, (T) IpM, (# ) 3joM, (♦) lOjiM, (A) 30jiM, measured every 
30 seconds for (a) 240 seconds, (b) 740 seconds, (a) Each point is a 
mean of 5 determinations with s.e. mean shown as vertical bars, (b) Each 
point is only 1 determination.
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it was decided not to calculate the results by this method. As SNP was used as the 
first agonist on each heart, the increase in flow induced by the agonists was expressed 
as a percentage of the increase in the flow induced by the initial dose of SNP (lOOpM) 
(% SNP flow (mls/min)). Where inhibitors or antagonists were used the increase in 
flow induced by the agonists was compared to the increase in flow induced by SNP 
(lOOpM) in the presence of the inhibitor or antagonist. However, due to the 
degradation of the condition of the heart over the experiment it seemed unwise to 
compare later agonist responses to the initial SNP response of a fl^ esh heart or not to 
consider any changes in the SNP response over the equilibration time given for the 
inhibitors and antagonists. Also this method of calculating the results seemed to 
magnify the errors inherent in the variable results obtained. The total flow induced by 
the agonist concentrations (agonist flow (mls/min)) also did not seem to be an ideal 
measurement of the responses because the individual agonist concentrations did not 
relax the vessels to a definitive degree in the same or different hearts as the amount of 
relaxation obtained seemed to depend on the contractile state of the vessels at the time 
the agonists were infused. Finally it was decided that the responses should be 
expressed as absolute increase in flow (mls/min), i.e. flow induced by the agonists 
(agonist flow) - the basal perfusion flow (control flow). This takes into account the 
contractile state of the vessels immediately prior to the agonists being infused but also 
the degradation of the condition of the heart over the experiment.
To study the effects ofL-NAME, 8 -SPT and PD 115,199 on the agonist concentration 
response curves the heart was equilibrated with these inhibitors for 2 0  minutes before 
the agonist concentration response curves were carried out. All the agonist 
concentration response curves were constructed non cumulatively, with a random 
order of agonists on unpaired hearts. Only one concentration response curve was 
carried out on each heart due to length of time required to construct one curve and the 
limited viability of the heart.
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EGsmis/mm values can be defined as the concentration of the agonist producing an 
absolute increase in flow of 3mls/min
^ ? A 2 can also be defined as the logarithm of the (dose-ratio -1) minus the logarithm of the 
molar concentration of the antagonist i.e. PA2  = log (dr-1) - log[A].
The results obtained from the isolated Langendorff perfused heart indicated that SNP 
modified the rate and force of contraction of the heart. As a consequence of this the effects of 
SNP on spontaneously beating isolated atria was ascertained and compared to the responses 
produced by isoprenaline on this tissue.
The effect of phenylephrine, L-NAME, 8 -SPT and PD 115,199 on the increase in flow 
induced by one concentration of SNP (lOOpM) and NECA (3{xM) and also on the 
basal perfusion flow through the heart was investigated. The basal perfusion flow and 
the agonist induced flows were measured before and after perfusion of the heart with 
these compounds and the % decrease in basal flow or % decrease in the agonist 
induced flows were calculated. Each heart was perfused for 20 minutes with only one 
inhibitor.
pECimk/min values (the negative logarithm of the EC^nik/min value) were calculated 
from the linear portion of individual log. concentration response curves by linear 
regression analysis. Potency of the agonists was expressed as ECgmis/min values 
calculated from the mean of the pECgmis/mln values. For PD 115,199, the dose-ratio 
for NECA was calculated as the ratio of the ECg^ i^g/^^  ^values in the presence and 
absence of one concentration of the antagonist and estimated pA% values were 
calculated as the negative logarithm of the (molar concentration of the antagonist 
divided by the dose-ratio -l}^
2.1.3. Rat isolated atria.
Male Wistar rats (300-400g) obtained fi*om the University of Surrey breeding unit 
were injected with 500 Units heparin i.v. via the tail vein 5 minutes prior to being 
killed by cervical dislocation. The heart was rapidly excised fi'om the thoracic cavity 
and plunged into ice cold Krebs Henseleit solution (mM: NaCl, 118; KCl, 4.7; 
NaHCOs, 25; Glucose, 11; MgS0 4 .7 H2 0 , 1.17; KH2PO4 , 1.2; CaCl2 .2 H2 0 , 2.5) 
whilst the excess lung and connective tissue were removed. The right atria was 
dissected fi'om the heart and mounted in 4ml organ baths containing Krebs Henseleit 
solution, maintained at 37°C and aerated with 95% O2  : 5% CO2  The atria were 
allowed to beat spontaneously under a resting tension of 2.5g and equilibrated for 1 
hour with isometric responses subsequently recorded with a Grass FT03 force
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displacement transducer and displayed on a Grass polygraph (model 79). To measure 
the effects of SNP and isoprenaline on the rate and force of contraction of the atria, the 
agonists were added non cumulatively and the atria were incubated with SNP for 5 
minutes, or in the case of isoprenaline until a stable response was produced 
(approximately 2-3 minutes). Changes in the rate of contractions were expressed as % 
increase in rate as compared to the control in the absence of the agonists, and changes 
in force of contraction were calculated as % increase in force as compared to the 
control in the absence of the agonists.
2.2. MATERIALS
PD 115,199 was kindly provided by Dr. M.G. Collis, Pfizer Central Research, 
Sandwich, U.K. whilst APNEA was provided by Professor R. A. Olsson, University of 
South Florida, USA. CGS 21680, CPA, DPCPX and 8-SPT were obtained from 
Research Biochemicals Inc., U.S.A. and heparin was supplied by Leo Laboratories 
Ltd., U.K. whilst all other compounds used were obtained from Sigma Chemical Co., 
U.K. Buffer salts were obtained from BDH Ltd. and Fisons and 95% 0%: 5% CO2  
was supplied by B.O.C.
CPA, MTA, and DPCPX were made up to lOmM in 20% ethanol, 0. IM HCl and 20% 
ethanol respectively. APNEA was made up at a concentration of 8mM in 70% 
dimethylsulphoxide (DMSO) whilst CGS 21680 was made up to lOmM in 7% DMSO 
for use in the isolated aorta and in 10% DMSO for the Langendorff heart preparation. 
All these compounds were then fijrther diluted in distilled water. PD 115,199 was 
made up to lOmM in 100% DMSO and diluted as required in 100% DMSO. All other 
compounds were made up in distilled water. The solvents used for dissolving the 
compounds had no effect on the responses of the tissues at the final concentrations 
used. Isoprenaline (lOmM) and phenylephrine (lOmM) were made up daily in distilled 
water. Noradrenaline (lOmM) was made up daily by dissolving in ascorbic acid
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solution (20|ig/ml) whilst heparin (25,000 Units/ml) was diluted to 5,000 Units/ml in 
normal saline solution. Adenosine and adenosine triphosphate (ATP) were made up in 
distilled water and their final concentrations checked using UV spectrophotometry. 
The absorbance of the solution was measured at 259nm and compared to the 
extinction coefficient for adenosine or ATP at this wavelength, 15.1 x 10-3M"lcm-l 
and 15.4 X 10-3M-lcm"l respectively.
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CHAPTER 3: 
RESULTS
4
Using a one-way ANOVA analysis followed by Dunnetts multiple comparison tests, the 
pECgo value for NECA was not significantly different to the pECgg value of CGS 21680 (p
> 0.05), the pECgo value for adenosine was not significantly different to that of CPA and
APNEA (p >0.05), whereas the pECgg values of NECA and CGS 21680 were significantly
different to the pECgo values of adenosine CPA and APNEA (p <0.01).
3.1. RAT THORACIC AORTA
Adenosine and several of its analogues induced relaxation of the noradrenaline 
contracted rat thoracic aorta producing an agonist potency order of NECA > CGS 
21680 > adenosine = APNEA = CPA > MTA (Figure values for the agonists
are given in Table 3. The maximal responses of these agonists varied, with the lowest 
maximal response being produced by CGS 21680 (approximately 40% inhibition) 
followed by NECA (approximately 60% inhibition). Although the concentration 
response curves of APNEA and adenosine did not plateau even at the highest 
concentration tested (300pM), their maximal values appear to be higher than that 
produced by NECA. The concentration response curve for CPA also did not reach a 
plateau at 300pM but its maximal response appears to be lower than that of APNEA 
and adenosine. MTA only induced relaxations at the highest concentration tested, 
therefore its maximal response could not be predicted. Acetylcholine was the most 
potent relaxing agent used on the rat thoracic aorta producing almost 1 0 0 % relaxation 
at 3|xM and an EC3 0  value of 0.04jxM (Figure 7).
The relaxations produced by the adenosine agonists were abolished by the mechanical 
removal of the endothelium, with the exception of the small residual responses seen at 
300pM for NECA, CPA and MTA (Figure 8 ). Removal of the endothelium did not 
affect the contractions induced by NA in the rat aortic rings (Figure 9a). At the 
submaximal concentration of lOOnM NA chosen to precontract the aortic rings, there 
was no difference in the tension developed in intact and endothelium denuded aorta 
(Figure 9a).
Equilibration of the aortic rings with L-NAME (30pM) also abolished the responses of 
the adenosine agonists, although again small residual responses were seen for all the 
agonists at the highest concentrations used (Figure 10). The relaxations induced by the 
endothelium independent vasodilator SNP in the presence and absence of L-
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Figures. Effect of removal of the endothelium on the
responses of adenosine analogues in the rat thoracic aorta
80-1
6 0 -
4 0 -
2 0 -
0 - 1
0.01 0.1 1 10 100 1000 0.01 0.1 1 10 100 1000
O 1 0 0 -,
8 0 -
6 0 -
4 0 -
2 0 -
0 - 1
0.01 0.1 1 10 100 1000
60-,
5 0 -
4 0 -
3 0 -
2 0 -
1 0 -
0 -J
0.01 0.1 1 10 100 1000
1 0 0 -,
8 0 -
6 0 -
4 0 -
2 0 -
0  J
0.01 0.1 1 10 100 1000
50-1
4 0 -
3 0 -
2 0 -
1 0 -
0 - 1
0.01 0.1 1 10 100 1000
Agonist Concentration (|liM)
Relaxations of the rat thoracic aorta precontracted with NA (lOOnM) 
induced by adenosine analogues in the presence (# ) and absence 
(■) of endothehum. (a) NECA, (b) CGS 21680, (c) Adenosine, (d) 
CPA, (e) APNEA, (f) MTA. Each point represents the mean of at 
least 4 determinations with s.e. mean shown as vertical bars.
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Figure 9. Effect of endothelium removal and L-NAME on the
NA induced contractions of the rat thoracic aorta.
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Contraction of the rat thoracic aorta induced by noradrenaline (a) 
in the intact (# ) and denuded (■ ) aorta, (b) in the presence (■ ) 
and absence ( • )  of L-NAME (30jiM). Each point represents the 
mean of at least 4 determinations with s.e. mean shown as vertical 
bars
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Figure 10. Effect of L-NAME on the responses of adenosine
analogues in the rat thoracic aorta
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Relaxations induced by adenosine analogues of the rat thoracic aorta 
precontracted with NA (lOOnM) in the presence (■ ) and absence (# ) of L-NAME 
(30|xM). (a) NECA, (b) CGS 21680, (c) Adenosine, (d) CPA, (e) APNEA, (f) 
MTA. Each point represents the mean of at least 4 determinations with s.e. mean 
shown as vertical bars.
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NAME (30[xM) were not significantly different (p^ 0.05, Students 'f  test. Figure 11). 
L-NAME (SOjiM) enhanced the contractions induced by NA, shifting the 
concentration response curve to the left by approximately ten fold (Figure 9b). 
However, at the noradrenaline concentration (lOOnM) used to precontract the aorta 
throughout the study, the responses induced by NA in the presence and absence of L- 
NAME were not significantly different (p 0.05, Students't' test). L-NAME (30pM) 
did not affect the relaxations induced by isoprenaline (25pM) (results not shown).
8 -SPT (50|xM) inhibited the relaxations produced by all the adenosine agonists with 
the exception of MTA, whose response at 300pM was slightly enhanced, although this 
was not significant (p> 0.05, Students't' test. Figure 12). However, the degree of 
inhibition and the dose-ratios obtained for 8 -SPT varied with the agonist used, with 
NECA being inhibited to the greatest extent (Table 3). In addition to shifting the 
agonist concentration response curves to the right, 8 -SPT also increased the maximal 
response of CGS 21680 from approximately 40% to 60% inhibition and increased the 
response induced by CPA at the highest concentration used (lOOpM).
MTA (lOOpM) also acted as an antagonist on the rat thoracic aorta (Figure 12). As 
with 8 -SPT, the degree of inhibition and the dose-ratios obtained for MTA varied with 
the agonist used, again with NECA being inhibited to the greatest extent (Table 3). 
Similar to 8 -SPT, MTA increased the maximal response of CGS 21680 from 
approximately 40% to 60% inhibition, but MTA also decreased the maximal response 
of NECA from approximately 60% to 40% inhibition (Figure 12).
The A2 a selective antagonist PD 115,199 (IpM) inhibited the relaxations induced by 
NECA and CGS 21680 shifting the concentration response curves to the right (Figure 
13). The dose-ratios produced for NECA and CGS 21680 in the presence of the 
antagonist were 30.2 and 6.2 (estimated pA% values of 7.5 and 6.7) respectively with 
NECA being inhibited to a slightly greater extent than CGS 21680 (Table 3). In
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Figure 11. Effect of L-NAME on the SNP induced
relaxation of the rat thoracic aorta
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Relaxations of the rat thoracic aorta precontracted with 
NA (lOOnM) induced by SNP in the presence (■ ) and 
absence (# ) of L-NAME (30pM). Each point represents 
the mean of at 4 determinations with the s.e. mean 
shown as vertical bars.
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Figure 12. Effect of 8-SPT and MTA on the relaxations of the rat 
thoracic aorta induced bv adenosine analogues
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(f) MTA. Each point represents the mean of at least 4 determinations with s.e. 
mean shown as vertical bars.
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Figure 13. Effect of PD 115.199 on the responses
to NECA and CGS 21680 in the rat thoracic aorta
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Relaxations of the rat thoracic aorta precontracted with 
NA (lOOnM) induced by (a) NECA and (b) CGS 21680 
in the presence (■) and absence (# ) of PD 115,199 
(IpM). Each point represents the mean of at least 4 
determinations with s.e. mean shown as vertical bars.
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addition, the maximal response induced by CGS 21680 was increased from 
approximately 40% to 80% in the presence of PD 115,199 and the maximal response 
to NECA also appears to be increased although a new maximum response was not 
achieved (Figure 13).
DPCPX (InM) did not alter the concentration response curves produced by APNEA 
and adenosine, but it potentiated the relaxations induced by CPA, shifting the 
concentration response curve slightly to the left, although this was not a significant 
effect (p> 0.05, Students't' test. Figure 14). No contractions to CPA (< IpM) were 
observed in the endothelium intact aorta, and in the presence of L-NAME (30pM) no 
contractions to CPA were seen in the presence or absence of a NA contraction 
(lOOnM) and an enhancement of the NA contraction was not observed when CPA was 
added prior to the NA (Figure 15).
3.2. RAT ISOLATED HEART
Adenosine, CGS 21680, NECA and CPA induced an increase in flow rate when 
infiised into the rat isolated heart Langendorff* preparation. The agonist potency order 
obtained was CGS 21680 > NECA > CPA = adenosine, with ECq^iR/mm values of 0.8 
pM, l.OpM, 52.0pM and 59.1pM. respectively (Figure 16). ATP had a similar 
potency to that of adenosine and CPA producing an ECc^ mk/min value of 38.2pM 
(Figure 16). The maximal response obtained for CGS 21680 was only 70% of that 
achieved by NECA. CPA and adenosine did not achieve a maximal response within 
the concentration range tested (Figure 16). When L-NAME (30pM) was infused into 
the heart over a 5 minute period using the same protocol as the adenosine agonists, it 
produced a small decrease in flow (0.3 ± 0.18 mls/min).
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Figure 14. Effect of DPCPX on the relaxations induced bv
APNEA. Adenosine and CPA in the rat thoracic aorta
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Relaxations induced by adenosine analogues of the rat thoracic aorta 
precontracted with noradrenaline (lOOnM) in the presence (■ ) and 
absence (# ) of DPCPX (InM). (a) APNEA, (b) Adenosine, (c) CPA. 
Each point represents the mean of at least 4 determinations with s.e. mean 
shown as vertical bars.
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Figure 15. Representative traces of some of the responses of
adenosine analogues in the rat thoracic aorta.
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Representative traces of the relaxations induced by the adenosine 
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contraction by CPA in the rat thoracic aorta.
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8 -SPT (50|iM) abolished the increase in flow produced by adenosine and its analogues 
with the exception of a small increase in flow (0.7 mls/min) produced by the highest 
concentration of NEC A (30|xM) (Figure 17).
In the presence of the Â2 a antagonist PD 115,199 (30nM), the increase in flow induced 
by NECA was inhibited, shifting the concentration response curve to the right (Figure 
18). The EC3„jis/uiin value calculated for NECA in the presence of PD 115,199 was 
3.9pM, producing a dose-ratio of 3.9 (estimated pA2  of 8 ). In the presence of a lower 
concentration of PD 115,199 (lOnM) the responses to CGS 21680 were almost 
abolished. As the increases in flow achieved by CGS 21680 in the presence of PD 
115,199 were very low producing a maximal response of only Iml/min increase in flow 
at lOpM CGS 21680, it was impossible to calculate a ECgmis/min value (Figure 18).
Perfusion of the heart with a nitric oxide synthase inhibitor L-NAME (30pM) for 30 
minutes caused an inhibition of the increase in flow rate induced by ATP, adenosine 
and its analogues, producing a rightward shift in the concentration response curves 
(Figure 19). For CPA and adenosine the shift was such that only the highest 
concentration of agonist (100p,M) produced a small increase in flow (1.02 mls/min and 
0.64 mls/min respectively) (Figure 19). It was impossible to obtain dose-ratios for CPA 
and adenosine in the presence of L-NAME due to the low potency of the compounds 
and the lack of responses produced within the agonist concentration range used.
In the presence of L-NAME (30pM) the responses for NECA and CGS 21680 were 
inhibited, shifting the concentration response curves to the right (Figure 19). As the 
maximal responses for these agonists in the presence of the inhibitor only reached 3 
mls/min it was impossible to calculate dose-ratio values for the agonists. However, the 
concentration curve for CGS 21680 was shifted approximately 30 fold to the right
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Figure 17. Effect of 8-SPT on the responses of adenosine
analogues in the rat isolated heart
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of 8-SPT (50pM). Each point is a mean of at least 4 determinations with 
s.e. mean shown as vertical bars.
68
Figure 18. Effect of PD 115.199 on the responses
to NECA and CGS 21680 in the rat isolated heart.
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Increase in flow induced by (a) NECA in the presence (■ ) and 
absence ( • )  of PD 115,199 (30nM) and (b) CGS 21680 in the 
presence (■ ) and absence (# ) of PD 115,199 (lOnM) in the rat 
isolated heart. Each point is a mean of at least 6 determinations with 
s.e. mean shown as vertical bars.
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Figure 19. Effect of L-NAME on the responses of adenosine
analogues on the rat isolated heart.
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I t
although this reduction did not quite reach significance (0.05 < p < 0.1)
while that for NECA was shifted 20 fold to the right in the presence of L-NAME when 
compared at an increase in flow rate of 2 mls/min. In addition, L-NAME appears to 
have decreased the maximal response achieved by NECA and CGS 21680. The 
maximal response of NECA decreased from 7.2 mls/min to 3.1 mls/min whilst that of 
CGS 21680 decreased from 5.1 mls/min to 2.9 mls/min (Figure 19).
L-NAME (30pM) inhibited the responses to ATP shifting the concentration response 
curve for ATP to the right, although small residual responses were seen at the highest 
concentrations of ATP used. This curve did not differ markedly from that produced by 
adenosine and CPA in the presence of L-NAME (Figure 20). Although the responses 
produced by ATP did not reach a plateau at lOOpM, it appears that ATP in the 
presence of L-NAME would achieve a lower maximal response than in the absence of 
L-NAME (Figure 20). The concentration response curves for SNP in the presence and 
absence of L-NAME were not significantly different (p> 0.05, Students t' test. Figure 
20).
Perftjsion of the heart with L-NAME (30pM), phenylephrine (lOOnM), or the 
adenosine antagonists 8 -SPT (lOOpM) and PD 115,199 (IfxM) significantly decreased 
the basal flow through the heart (p < 0.05, paired Students 't' test), whereas perfiision 
with Krebs solution only decreased the basal flow by 1.18 ± 11.6% (Table 4). The 
increase in flow induced by SNP (lOOpM) was significantly reduced after perfiision of 
the heart with L-NAME, phenylephrine, 8 -SPT and PD 115,199, but was also 
significantly decreased when the heart was perfused with Krebs solution (p < 0.05, 
paired Students 'f  test. Table 4). Similarly, the increase in flow induced by NECA (3 p. 
M) was also reduced by perfiision of the heart with Krebs solution or PE 
Students't' test), and also with L-NAME or 8 -SPT (p < 0.05, Students't' test. Table 
4). However, perfiision of the heart with PD 115,199 reduced the increase in flow 
produced by NECA, although this was not significant (Table 4). Using a one-way 
ANOVA analysis followed by a Dunnetts post-hoc test a significant difference (p <
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0.05) was observed between the reduction in the NECA induced response caused by 8 - 
SPT and that caused by L-NAME and Krebs solution alone.
Perfusion of the heart with L-NAME (30pM) significantly decreased the force of 
contraction of the heart by 28%, from 2.9 ± 0.2 to 2.0 ± 0.2 g tension (p < 0.05, 
Students 't' test). Infusion of SNP (lOOpM) however, increased the force of 
contraction both in the presence and absence of L-NAME (24.3% and 28.9% 
respectively). The overall force generated by SNP in the presence of L-NAME (30p 
M) (1.96 ± 0.17g to 2.45 ± 0.2g was lower than that generated in the absence of L- 
NAME (30pM) (2.91 ± 0.15g to 3.62 ± 0.2g) although the percentage increase 
obtained was the same.
In unstimulated, spontaneously beating hearts SNP increased the rate of contraction of 
the heart from 183.8 ± 9.9 beats/min prior to the SNP infusion to 247.5 ± 9.2 
beats/min during the SNP infusion producing a 25% increase in heart rate.
3.3. RAT ISOLATED ATRIA
In the rat isolated atria, SNP (lOOpM) induced a small increase in the rate of 
contraction of the atria (4.6% ±1.3 increase from control) but had no effect on the 
force of contraction (Figure 21). Isoprenaline (lOnM) however, caused an significant 
increase in the rate and force of contraction of the atria (59.5% ± 5.0 and 137.3% ± 
17.8 respectively, p < 0.05, Students't' test. Figure 2 1 ).
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Figure 20. Effect of L-NAME on the responses to
ATP and SNP in the rat isolated heart
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Increase in flow induced by ATP and SNP in the rat isolated 
heart in the presence (■ ) and absence (# ) of L-NAME 
(30jiM). Each point represents the mean of 4 determinations 
with s.e. mean shown as vertical bars.
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Figure 21. Representative traces of the responses to SNP
and isoprenaline in the rat isolated atria.
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Representative traces of the changes in the (a) rate of 
contraction and (b) force of contration of the rat isolated 
atria induced by SNP (lOOpM) and isoprenaline (lOnM).
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CHAPTER 4: 
DISCUSSION
4.1. RAT THORACIC AORTA
The presence of adenosine receptors in the rat thoracic aorta has been previously 
reported by Moritoki et al. (1990), Rose'Meyer and Hope, (1990) and Conti et al. 
(1993). In these studies the 5' substituted analogue NECA was found to be more 
potent than the substituted A% selective agonist R-PIA, which according to the 
agonist potency orders ascertained for the adenosine receptors (see Table 1 in the 
introduction) would indicate the presence of A2  receptors on this tissue. In this study, 
adenosine agonists induced relaxations of the rat thoracic aorta with a potency order of 
NECA > CGS 21680 > adenosine = APNEA = CPA > MTA again indicating the 
presence of A% receptors as NECA is more potent than the N^ substituted Ai selective 
agonists CPA and APNEA. It was also found that the 2-substituted agonist CGS 
21680 has a comparable potency to NECA producing EC3 0  values of 0.5pM and 0.2p 
M respectively. Conti et al. (1993) and Moritoki et a l (1990) also found that CGS 
21680 and NECA were comparable, potent agonists on the aorta and it has also been 
reported in binding studies in the rat striatum that both of these compounds produced 
similar affinity values (14nM and 12nM respectively, Jarvis et al., 1989). As CGS 
21680 is considered to be selective for the A%a receptor subtype (Bruns et a l, 1986; 
Hutchinson et a l, 1989), the high potency of CGS 21680 in this study and in those 
studies by Conti et al. (1993) and Moritoki et a l (1990) suggests that the receptors 
present on the aorta are actually of the A2a receptor subtype although the receptors 
reported by Conti et al. (1993) and Moritoki et a l (1990) were only classified as A2  
receptors. Similar potency orders have been seen in a variety of tissues including the 
porcine and dog coronary arteries, rat pheochromocytoma (PC 12) cells, human 
neutrophils and platelets where the receptor has been classified as the A2 a receptor 
subtype due to the high potency of A2 a selective agonists such as CGS 21680 and CV 
1808 (Balwierczak et a l, 1991; Kennedy et a l, 1992, Gurden et a l, 1992; Hide et a l, 
1992).
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In contrast to Conti et a l (1993) who showed 100% relaxations of the rat thoracic 
aorta by all of the adenosine agonists, in this study the maximal responses obtained 
varied depending on the agonist used. The maximal values for CPA, adenosine, 
APNEA and MTA were hard to predict due to their low potencies, whilst NECA 
produced a maximal response of 60% relaxation and CGS 21680 only produced 40% 
relaxation. This discrepancy could be explained by the use of a different strain of rat 
(Sprague-Dawley), or more likely the different contractile agonist (PGp2 a) used by 
Conti et a l (1993). It has also been shown by Moritoki et a l  (1990) that in 4 week 
old rats, adenosine produced a maximal response of 80% relaxation when using NA as 
the contractile agonist. However, in the thoracic aorta of 8  weeks old rats 
(approximately the age of the rats used in our study) the maximal response induced by 
adenosine was decreased slightly so it did not exceed 70-75% relaxation. Also in 8  
week old rats, a 30 fold higher concentration of adenosine was required to produce a 
relaxation comparable to that achieved at 4 weeks of age. Increasing the age of the 
rats to 1 2  weeks again the adenosine response was decreased and although a plateau 
was not achieved, adenosine at the highest concentration used (300pM) only induced 
approximately 30% relaxation. It would appear that the dilator response to adenosine 
decreases with age due to a decrease in the number of purinoceptors, or a decrease in 
the ability of the endothelium to produce EDRF, or a decrease in guanylate cyclase 
activity leading to a decrease in the formation of cGMP (Moritoki et a l, 1990). 
Therefore it may not have been possible to achieve 1 0 0 % relaxations to the adenosine 
agonists used in this study as the older age of the rats may have prevented maximum 
relaxations being obtained. This may also explain why Conti et al. (1993) using 
younger rats (150-200g, approximately 5 weeks old) obtained a greater degree of 
relaxation to the adenosine agonists. The major difference between the studies of 
Conti et al. (1993), Moritoki et al (1990) and this study is the method of agonist 
dosing. Cumulative dosing was used in the other studies whereas single dosing was
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used in our study due to the unstable nature of the noradrenaline contraction and the 
agonist relaxations. Another suggestion for the different maximal responses achieved 
by NECA and CGS 21680 is the possibility that NECA is acting as a fiill agonist on 
this tissue whereas CGS 21680, only achieving 6 6 % of the NECA maximal response, 
may be acting as a partial agonist. If this was the case, CGS 21680, acting at the same 
receptor as NECA, would behave as antagonist inhibiting the response to NECA. 
Indeed, in the rat thoracic aorta CGS 21680 has been shown to inhibit NECA induced 
relaxations (Prentice and Hourani, 1995). Other examples where CGS 21680 has been 
shown to have a reduced efficacy compared to NECA include the A2 a mediated 
stimulation of cAMP production in both human platelets and cultured guinea-pig 
coronary endothelial cells where the maximal response to CGS 21680 was 65% and 
50% of the NECA response respectively (Cristalli et al., 1994; Schiele and Schwabe, 
1994).
The 5’ endogenous nucleoside MTA induced relaxations of the thoracic aorta only at 
the highest concentration (300|xM) used and therefore was acting as a very weak 
agonist. This response was not inhibited by the non-selective antagonist 8 -SPT 
suggesting that the MTA induced relaxations were not mediated via the A2 a receptors 
present on the aorta but via another site which is resistant to blockade by 8 -SPT. 
Brackett and Daly (1991) also reported that in the guinea-pig trachea (A2b receptors) 
MTA acts as a very weak agonist (EC5 0  = 225|xM) whose responses were not 
inhibited by 8 -SPT (90|xM) concluding that MTA acts via a xanthine-resistant 
mechanism. These results are contrary to those reported by Munshi et al. (1988) in the 
rabbit jejunum, (containing A2  receptors which were not fiirther classified), and 
Nishida et al. (1985) and Daly and Padgett (1992) in the rabbit aorta and rat PC12 
cells (which contain A2 a receptors) where MTA acts as a weak or partial agonist 
whose effects can be antagonised by the presence of 8 -SPT (lOO i^M) and theophylline 
(lOOpM). The possibility that MTA may act as an antagonist on these tissues was not
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considered (Nishida et a l, 1985; Daly and Padgett, 1992). MTA also has been shown 
to act as an agonist on the A  ^ receptors of the rat cell membrane and the rat 
cerebellum (Daly and Padgett, 1992; Munshi et a l, 1988). It has previously been 
reported that at the A2b receptors in VA13 human fibroblasts and neuroblastoma cells 
MTA appears to act as an antagonist producing Kj values of 8.2 and 4.4 i^M 
respectively (Bruns et a l, 1986; Munshi et a l, 1988). However, it has also been 
reported that MTA can inhibit the A2a receptor mediated effects of adenosine on 
platelets (Agarwal and Parks, 1980). MTA has been reported to act as a xanthine 
sensitive, weak or partial agonist at A2a receptors, and an antagonist at A2b receptors 
(Daly and Padgett, 1992). However, on the A2 a receptors in this study on the rat aorta 
MTA appears to act as an antagonist producing similar dose-ratios to those of 8 -SPT 
but MTA also appears to act as a xanthine-resistant, weak agonist on another site on 
the aorta.
The A2 a selective antagonist PD 115,199 inhibited the relaxations of the rat thoracic 
aorta induced by NECA and CGS 21680, although the responses to NECA were 
antagonised to a slightly greater extent than the responses of CGS 21680. In this 
study, a pA2  value of 7.5 was produced for NECA which is comparable to the 
published affinity of PD 115,199 in binding at the A2 a receptors in the rat striatum (pKj 
of 7.8, Bruns et a l, 1987). This suggests that the relaxations induced by NECA were 
mediated via the A2a receptors present on the rat thoracic aorta. CGS 21680 
however, was inhibited by PD 115,199 to a slightly lesser degree than NECA 
producing a pA2  value of 6.7 suggesting that although it is likely that CGS 21680 is 
acting at the A2a receptors, another receptor site may also be involved.
Both MTA, when used as an antagonist, and the non selective antagonist 8 -SPT 
inhibited the responses to all the agonists on the rat aorta, with the exception of the 
relaxant responses to MTA which were resistant to blockade by 8 -SPT. However, as
79
with PD 115,199, the dose-ratios in the presence of 8 -SPT and MTA showed that 
these antagonists inhibited the effects of NECA to a greater extent than the other 
agonists. At the A%a receptors present in the porcine coronary artery King et al.
(1990) reported a pA% value of 5.3 for NECA in the presence of 8 -SPT which is 
comparable to the pA% value of 5.6 produced for NECA in the presence of 8 -SPT in 
this study. Similarly MTA antagonised the responses to NECA producing a pA] of 6 .1 
which is consistent with the published binding affinity at the A%a receptors in the rat 
striatum (pKf of 6 , Daly and Padgett, 1992). These results suggest that the relaxations 
induced by NECA are mediated via the A%a receptors present on the aorta. The other 
agonists used in this study were not inhibited by 8 -SPT and MTA to the same extent as 
NECA producing lower pA2  values of 4.2-5.0, suggesting that these agonists may not 
be solely acting on A2a receptors but may also be acting on a different second site 
which shows some resistance to blockade by 8 -SPT and MTA. In the guinea-pig 
trachea (which contains A2b receptors) it has also been shown that NECA was 
inhibited by 8 -SPT to a greater extent than 2-CADO, R-PIA and CHA (dose-ratios of 
16 and 4.2-5.4 respectively) and also in the bovine coronary arteries where 8 -PT 
produced a greater shift in the concentration response curve to NECA than to 2- 
CADO (Brackett and Daly, 1991; Sabouni et al., 1989). The maximum responses 
achieved by some of the adenosine agonists were altered in the presence of PD
115,199, MTA and 8 -SPT. For example, MTA decreased the maximal response 
achieved by NECA and both 8 -SPT and PD 115,199 appeared to slightly increase the 
maximal response to NECA although a new maximum value was not reached. The 
maximal responses to CGS 21680 were increased by PD 115,199, MTA and 8 -SPT so 
that CGS 21680 achieved a similar maximum response to that produced by NECA. 
This suggests that although CGS 21680 may be acting as a partial agonist and NECA 
acting as a full agonist at the A2 a receptors, in the presence of the adenosine 
antagonists, CGS 21680 and NECA may be activating a second site at which CGS 
21680 may be acting as a full agonist achieving a similar maximum response to NECA.
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Enhancement of the maximal response of adenosine has also been seen, in the guinea- 
pig trachea in the presence of antagonists such as 8 -PT and DPCPX (Collis et al., 
1987; 1989). Overall the results obtained with the antagonists PD 115,199, 8 -SPT and 
MTA suggests that NECA is acting on the A%a receptors present on the rat thoracic 
aorta. It is likely that the CGS 21680, CPA and adenosine are also acting on the A%a 
receptors but it also appears that their responses are also mediated via a different 
second site which displays resistance to blockade by 8 -SPT and MTA. Whereas MTA 
acts as an antagonist on the A%a receptors it also appears to act as an agonist on this 
second xanthine-resistant site present on the rat thoracic aorta.
These unusual findings could be explained by the presence of other receptors on the 
thoracic aorta. One possible candidate is the A% receptor, however in this study little 
evidence could be found for this since DPCPX, an Ai selective antagonist did not 
inhibit the relaxations induced by the A% agonists APNEA, CPA and adenosine and 
contractions to low concentrations of CPA were not seen. Likewise, Conti et al. 
(1993) reported that in the rat aorta there was no indication of contractile Ai receptors 
and the concentration response curves of both NECA and CGS 21680 were not 
affected by DPCPX (lOOnM) so concluding that A% receptors were not present on this 
tissue. The small potentiation of the relaxations induced by CPA in the presence of an 
Ai selective concentration of DPCPX (InM) may indicate the presence of a small 
population of contractile Ai receptors on the aorta. These results are in contrast to 
those reported by Farmer et al. (1988) and Stoggall and Shaw (1990) in the guinea-pig 
trachea and aorta where A% agonists R-PIA, 2-CADO and CHA produced biphasic 
concentration response curves with contractions at low concentrations of the agonists 
and relaxations at higher concentrations indicating the presence of both contractile A% 
and relaxant A% receptors on the same tissue.
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The differing degrees of antagonism by 8 -SPT and the weak xanthine-resistant relaxant 
effects of MTA could also indicate the presence of A3 receptors in addition to A2a 
receptors on the thoracic aorta. This receptor was originally cloned from the rat 
striatum and was described as being insensitive to classical xanthine antagonists such as 
8 -SPT and DPCPX (Zhou et al., 1992). Also, in the pithed rat the hypotensive 
responses induced by some adenosine agonists such as APNEA, R- and S-PIA were 
shown to have a component which was resistant to antagonism by 8 -SPT (Fozard and 
Carruthers, 1993a; 1993b; Carruthers and Fozard, 1993). These responses were found 
to be mediated via an A3 receptor present on mast cells (Hannon et al., 1995). 
APNEA and CPA are Ai selective agonists but show some selectivity for the A3 
receptors over the A2 a receptors (1.5 and 2 fold respectively), whereas CGS 21680 is 
an A2 a selective agonist which shows 39 fold selectivity for the A2 a over the A3 
receptor and NECA is a non selective agonist which has a 11 fold selectivity for the 
A2a receptor versus the A3 receptor (Kim et a l, 1994a; Van Galen et ah, 1994). 
Therefore if a combination of both A3 and A2 a receptors were present on the thoracic 
aorta, CGS 21680 would act preferentially on the A2 a receptors, NECA would act on 
both receptors, although NECA would have a slightly greater preference for the A2 a 
receptors over the A3 receptors, and APNEA and CPA would act equally on both A2 a 
and A3 receptors. In these circumstances, 8 -SPT would antagonise the effects of CGS 
21680 to the greatest degree, followed by NECA and then APNEA and CPA to the 
least extent due to the resistance of the A3 receptor to blockade by 8 -SPT. However, 
it can be seen from the dose-ratios produced for 8 -SPT that in this study NECA was 
inhibited to the greatest extent, whilst CGS 21680 was inhibited to a similar degree as 
CPA and APNEA. Therefore it is unlikely that the different antagonism of the agonist 
responses by 8 -SPT can be explained by the presence of A3 receptors.
The relaxations produced by the adenosine agonists on the rat thoracic aorta were 
virtually abolished by the mechanical removal of the endothelium, suggesting that these
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responses were endothelium-dependent. The finding that the adenosine agonist 
responses were essentially abolished by the nitric oxide synthase inhibitor L-NAME 
(30jaM), whilst the relaxation induced by the endothelium-independent agonist sodium 
nitroprusside (SNP) was unaffected, implied that adenosine agonist induced relaxations 
of the aorta occur through an endothelium-dependent mechanism involving the nitric 
oxide pathway. However, Moritoki g/ al (1990), RoseMeyer & Hope (1990) and 
Yen et a l (1988) all reported that mechanical removal of the endothelium attenuated 
rather than abolished the relaxations induced by the adenosine agonists leading them to 
conclude that on the rat aorta the adenosine agonist induced relaxations are only 
partially endothelium-dependent. An explanation for these different results could be 
due to the degree of mechanical rubbing used to denude the endothelium. It was found 
in our study that gentle rubbing was sufficient to abolish the relaxations to 
acetylcholine but more vigorous rubbing was required to abolish the responses to the 
adenosine agonists. If the aorta was only gently rubbed, relaxations to the adenosine 
agonists were produced giving the impression that the agonist responses had only been 
attenuated and therefore were only partially endothelial-dependent. RoseMeyer and 
Hope (1990) also found that haemoglobin (lOfxM), which inhibits the action of nitric 
oxide by binding and reacting with nitric oxide to form NO-haem complexes, inhibited 
the response to NECA by 102 fold, shifting its concentration response curve to the 
right. Moritoki et al (1990) also reported that both haemoglobin (lOnM) and the 
soluble guanylate cyclase inhibitor methylene blue (0.1-3fxM) inhibited the relaxations 
induced by adenosine (30|iM) in endothehum intact aorta but not in endothelium 
denuded aorta. These results provide fiirther evidence that the responses induced by 
the adenosine agonists in the rat thoracic aorta are endothelium-dependent and occur 
via the nitric oxide pathway.
In conclusion, these results suggest that adenosine analogues induce relaxations of the 
rat thoracic aorta by an endothelium-dependent mechanism which involves the nitric
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oxide pathway. However, the results obtained using the adenosine antagonists PD
115,199, 8 -SPT and MTA were not straightforward. NECA induced relaxations of the 
aorta were mediated via an A2 a receptor. CGS 21680, CPA and adenosine were not 
inhibited by the antagonists to the same extent as NECA suggesting that their 
responses were mediated via A2 a receptors but also via a second site displaying some 
resistance to blockade by 8 -SPT and MTA. The different degrees of antagonism and 
the xanthine-resistant effects seen in this study do not appear to involve A% or 
xanthine-resistant A3 receptors. Whereas MTA has previously been shown to act as an 
antagonist on A2b receptors and a xanthine sensitive agonist on A2 a receptors (Bruns 
et al., 1986; Daly and Padgett, 1992), it appears that in this study MTA acts as an 
antagonist on the A2 a receptors but also as a xanthine-resistant agonist at the second 
site. Although CGS 21680 appears to act as a partial agonist on the A2 a receptors of 
the rat aorta, in the presence of the adenosine antagonists CGS 21680 appears to act as 
a full agonist at the second site achieving a similar maximum response to NECA. The 
differing degrees of antagonism by 8 -SPT and the xanthine-resistant effects of MTA 
shown here in the rat thoracic aorta appear to be similar to the responses shown in the 
guinea-pig trachea (Brackett and Daly, 1991), indicating the possibility that the 
receptors or sites present on these two tissues may be identical.
4.2. RAT ISOLATED HEART AND ATRIA
To investigate the effects of adenosine analogues in the rat isolated heart a 
Langendorff constant pressure system was employed. Using this method the heart is 
perfused in a retrograde manner, which closes the aortic valves so the perfusate 
circulates through the coronary vessels rather than through the heart chambers. The 
perfusate solution, which will drain from the heart via the coronary sinus and the cut 
vena cava or pulmonary artery, can be collected as effluent underneath the heart for 
measurement of the coronary flow. When the pressure is maintained at a constant
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level a change in the coronary flow through the heart gives a general indication of the 
change in coronary vessel tone. For example, an increase in the coronary flow 
indicates a decrease in vascular tone i.e. vasodilation and conversely a decrease in flow 
suggests an increase in vessel tone i.e. vasoconstriction. However, the heart is a 
complex system which makes measurement of the flow through the heart problematic. 
Other factors can influence the vasodilations induced by the adenosine agonists, for 
example, the vasodilation observed will depend on the basal tone of the coronary 
vessels. It is possible that a greater basal tone will lead to physiological antagonism of 
the agonist vasodilator responses and therefore a reduction in the vasodilation 
observed. Therefore any compound which alters the vessel tone will consequently 
alter the vasodilation achieved by the adenosine agonists. As the heart fimctions as a 
whole a change in one parameter, such as a change in flow rate, may consequently 
affect other heart parameters, for example force or rate of contraction. If these 
changes are caused by a drug prior to the construction of agonist concentration 
response curves this may complicate the interpretation of the changes in the flow rate 
through the heart. In this study on the rat heart the experiments to determine the effect 
of adenosine agonists on the flow through the heart have been carried out by two 
different protocols. Initially concentration response curves for ATP, SNP and the 
adenosine agonists were performed in the presence and absence of the nitric oxide 
synthase inhibitor L-NAME and the adenosine antagonists 8 -SPT and PD 115,199 on 
unpaired hearts. However, it became apparent that some of the inhibitors caused 
vasoconstriction so that physiological antagonism of the agonist responses could not 
be ruled out and hence interpretation of these results became more complicated. To 
clarify the results the effect of these inhibitors and the vasoconstrictor phenylephrine 
on the basal flow and the increases in flow induced by SNP and NECA were 
investigated using a protocol involving paired results in individual hearts. The use of 
the different protocols may make the interpretations of the results easier. Initially, the 
effect of the adenosine antagonists and L-NAME on the full agonist concentration
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response curves were investigated then the results were subsequently re-examined in 
the light of the effect of phenylephrine on the coronary arteries and the involvement of 
physiological antagonism in the agonist responses.
In the rat isolated heart the adenosine agonists produced an increase in coronary flow 
through the heart indicating vasodilation of the coronary vessels. An agonist potency 
order of CGS 21680 > NECA > CPA = adenosine was produced suggesting that, as 
the 5' substituted agonist NECA is more potent than the N^ substituted agonist CPA, 
the adenosine receptors present on the rat coronary arteries are A2  receptors. CGS 
21680 has a comparable if slightly greater potency than NECA in this study producing 
FCgmis/min values of 0.8pM and l.OpM respectively. Similar findings were shown in 
the studies in the rat heart by Ueeda et al (1991b) and Hutchinson et al. (1989) where 
the potency values of l-2nM and 5nM were produced by CGS 21680 and NECA 
respectively. In the earlier study on the rat thoracic aorta both of these compounds 
had similar potency values, although the order was reversed and NECA was slightly 
more potent than CGS 21680. As CGS 21680 is considered to be selective for A2  ^
receptors, the high potency of this agonist in the isolated heart would suggest that the 
receptors present on the coronary arteries are of the A2 a subtype (Bruns et a l, 1986; 
Hutchinson et a l, 1989). These results are consistent vrith the findings shown in other 
studies in the rat heart, where a high correlation was produced between the order of 
agonist affinities for binding to A2 a receptors in the rat striatum and the order of 
agonist potencies mediating reduction in the coronary flow in the rat heart (Hamilton 
et a l, 1987; Oei et a l, 1988). Agonist potency orders similar to those seen in this 
study can be seen in isolated coronary arteries fi'om other species, for example, 
porcine, bovine, guinea-pig and canine coronary arteries (Abebe et a l, 1994; Conti et 
a l, 1993; Vials and Bumstock, 1993; Gurden and Kennedy, 1992) as well as other 
blood vessels such as the rat aorta and rabbit hepatic arterial bed (Moritoki et a l, 
1990; Mathie et a l, 1991). Using A2  ^ selective agonists such as CGS 21680 and CV
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1808 the vasodilation of these blood vessels was shown to be mediated via A2 a 
receptors.
ATP is normally considered to be an endothelium-dependent ? 2  purinoceptor agonist 
mediating vasodilation of blood vessels via ? 2y receptors (De Mey and Vanhoutte, 
1981; Kennedy et a l, 1985). ATP was initially used in this study to provide an 
endothelium-dependent vasodilation which would be abolished by the presence of a 
nitric oxide synthase inhibitor L-NAME. The vasodilations of the adenosine agonists 
in the presence and absence of L-NAME could then be compared to an endothelium- 
dependent agonist such as ATP as well as an endothelium-independent agonist such as 
SNP. However, it has been shown that during passage through the coronary bed ATP 
can be sequentially dephosphorylated by ectonucleotidases to produce adenosine 
(Fleetwood et a l, 1989). Subsequently, the adenosine can stimulate the Pj (A2 )^ 
receptors to induce vasodilation of the coronary vessels. ATP caused an increase in 
coronary flow through the heart with a potency similar to that produced by adenosine 
and CPA. This suggests that ATP is being degraded to adenosine before acting via the 
Pj receptors on the coronary arteries, although evidence of antagonism by the non 
selective Pj antagonist 8 -SPT or fiirther work with ectonucleotidase inhibitors would 
be required to confirm it.
Similar to the earlier study on the isolated rat aorta the maximal response produced by 
CGS 21680 was only 70% of the NECA maximal response (5 and 7mls/min increase in 
flow respectively). This suggests that NECA is acting as a full agonist and CGS 21680 
is acting as a partial agonist on the A2a receptors of the coronary vessels. CGS 21680 
has also been reported to act as a partial agonist on A2 a receptors present on human 
platelets and cultured guinea-pig coronary endothelial cells where the maximum 
response to CGS 21680 was 65% and 50% of the NECA maximum response 
respectively (Cristalli et a l, 1994; Schiele and Schwabe, 1994). The different maximal
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responses produced by NECA and CGS 21680 could also be due to the presence of 
two receptors on the coronary arteries with different maximum values, for example, 
the presence of A2b receptors as well as A2 a receptors. As CGS 21680 is an A2 a 
selective agonist it would preferentially stimulate the A2a receptors whereas NECA is a 
potent agonist at both A2  ^ and A2y receptors and therefore would stimulate both 
receptors. In this instance NECA would have a greater maximal response than CGS 
21680 due to the combination of the responses produced via both A2 a and A2y 
receptors as long as maximum value achieved by the stimulation of A2y receptors is 
greater than that achieved by the stimulation of A2  ^receptors. However, the presence 
of A2b receptors cannot be determined directly as selective antagonists for this 
receptor are not available, although they can be inferred by the lack of antagonism of 
adenosine agonist responses by an A2  ^selective antagonist such as PD 115,199.
The non-selective antagonist 8 -SPT abolished the increases in flow induced by all of 
the adenosine agonists confirming that Pj purinoceptors mediate this response. This 
would also suggest that xanthine-resistant responses and A3 receptors are probably not 
involved in mediating coronary vasodilation. This is contrary to the rat aorta where, in 
comparison to NECA, the other adenosine agonists displayed some resistance to 
blockade by 8 -SPT as the relaxations induced by NECA were inhibited by 8 -SPT to a 
greater extent than the relaxations induced by the other agonists.
The A2a selective antagonist PD 115,199 (30nM) inhibited the responses induced by 
NECA in the isolated heart shifting the concentration response curve to the right. A 
dose-ratio of 3.8 was produced yielding an estimated pA2  value of 8  which is 
comparable to the affinity of PD 115,199 in binding at A2  ^receptors in the rat striatum 
(pKi of 7.8). This suggests that the receptors present on the rat coronary arteries are 
of the A2 a subtype (Bruns et al., 1987). A lower concentration of PD 115,199 (lOnM) 
virtually abolished the responses induced by CGS 21680 in the rat heart producing a
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maximal response of Iml/min increase in flow at lOpM CGS 21680. As PD 115,199 
not only shifted the concentration response curve for CGS 21680 to the right in a non­
parallel manner but also depressed the maximum, it is possible that PD 115,199 may 
not be acting as a simple competitive antagonist at the A2 a receptors present on this 
tissue. It is possible that PD 115,199 is acting as a non-competitive or irreversible 
antagonist to produce the changes in the CGS 21680 concentration response curve 
(Kenakin et a l, 1987). It has been previously suggested that NECA is acting as a full 
agonist and CGS 21680 is acting as a partial agonist at the A2  ^ receptors present on 
the coronary arteries. In the presence of a non-competitive/ irreversible antagonist the 
concentration response curve of a full agonist with a receptor reserve would be shifted 
to the right in a parallel manner until the reserve has been depleted. The concentration 
response curve of a partial agonist with no receptor reserve would be shifted to the 
right but in a non-parallel manner as the maximum will be decreased. By definition, a 
partial agonist must occupy all the receptors to elicit its full response. In the presence 
of a non-competitive antagonist the number of receptors available to the agonist is 
reduced due to the presence of the antagonist. Therefore, the maximum response 
achievable by the partial agonist has been reduced, indicated by the decrease in the 
maximum value of the agonist concentration response curve. If PD 115,199 was a 
non-competitive/ irreversible antagonist the results obtained in this study would be 
consistent with NECA acting as a full agonist and CGS 21680 acting as a partial 
agonist on the A2 a receptors present in the coronary vessels. Non-competitive effects 
such as a decrease in B^ax values have been seen in binding at A2 a receptors in the rat 
striatum and at A  ^ receptors in the rat brain and guinea-pig atria using adenosine 
antagonists such as CGS 15943 and PACPX (Williams et al., 1987b; Bumstock and 
Hoyle, 1985). However, it is unlikely that PD 115,199 is acting as a non-competitive/ 
irreversible antagonist as changes in B^ a^x values were not seen in binding at A2 a 
receptors in the rat striatum (Bmns et a l, 1987).
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Perfusion of the heart with the nitric oxide inhibitor L-NAME (30|xM) abolished the 
responses to CPA and adenosine whilst shifting the concentration response curves to 
CGS 21680 and NEC A to the right by approximately 30 fold and 20 fold respectively 
(measured at 2ml/min increase in flow). The CPA and adenosine responses were 
abolished due to the low potency of these agonists in the absence of the inhibitor. This 
could suggest that the increases in flow induced by these adenosine agonists are 
mediated partly via an endothelium dependent mechanism involving the nitric oxide 
pathway and partly via receptors on the vascular smooth muscle. Alternatively the 
concentration of L-NAME (30pM) used in the rat heart may not be high enough to 
abolish the agonist induced vasodilations, although this is unlikely as the relaxations 
induced by the adenosine agonists in the rat aorta were virtually abolished by the same 
concentration of L-NAME. L-NAME also attenuated the responses induced by ATP 
shifting the concentration response curve to the right, also suggesting that ATP 
(possibly through conversion to adenosine) may be acting through a partially 
endothelium-dependent mechanism. The effect of L-NAME on other endothelium 
dependent vasodilators such as acetylcholine, bradykinin and the calcium ionophore 
A23187 was investigated but it was found that the responses produced by these 
agonists were not very consistent or reproducible both in the presence and absence of 
L-NAME so the use of these agonists were not pursued. The concentration response 
curve produced by the endothelium-independent vasodilator SNP was shifted slightly 
to the right in the presence of L-NAME, although there was no significant difference 
between the two curves (p> 0.05, Students't' test). Nitric oxide inhibitors such as L- 
NAME and L-NNA have also been reported to inhibit the responses induced by 
adenosine agonists in other blood vessels including the guinea-pig coronary artery, rat 
renal artery and the rabbit pulmonary artery (Vials and Bumstock, 1993; Martin and 
Potts, 1994; Steinhom et al., 1994). However, the majority of the blood vessels 
studied have not been examined for endothelium dependency or appear to be 
independent of the endothelial nitric oxide pathway (see Table 2).
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Whilst carrying out the experiments with L-NAME it became apparent that other 
factors were influencing the vasodilator responses produced by the adenosine agonists. 
For example, whilst constructing the agonist concentration response curves the 
vasodilator responses appeared to depend on the initial flow rate through the heart and 
also perfusion of L-NAME appeared to decrease the basal flow and force of 
contraction of the heart. Using the protocol above to produce agonist concentration 
response curves on separate hearts, it was impossible to assess what effect these 
changes were having on the adenosine vasodilator responses. Construction of full 
agonist concentration response curves in the presence and absence of an antagonist on 
one heart in a paired fashion was impossible due to limited viability of the heart, 
therefore the effect of L-NAME, 8 -SPT and PD 115,199 on one concentration of SNP 
(lOOpM) and NEC A (3pM) was investigated in a paired fashion on each heart (Table 
4). This concentration of NEC A was chosen as it produced a similar increase in flow 
to that achieved by SNP (lOOpM). The hearts were perfused with the inhibitors for 20 
minutes to investigate their effects on the basal flow and the agonist induced increases 
in flow in the isolated heart. L-NAME caused a significant decrease in the basal flow 
through the heart (p < 0.05, Students't' test). Basal production of nitric oxide causes 
a basal relaxant tone of the coronary vessels. Removal of this tone by inhibition by L- 
NAME would effectively cause vasoconstriction and consequently a decrease in flow. 
The adenosine antagonists 8 -SPT and PD 115,199 also caused a significant decrease in 
the basal flow through the heart. It is likely that adenosine is being continually released 
into the lumen of the coronary vessels and is stimulating the A2 a adenosine receptors 
present on the coronary vessels to produce vasodilation and a relaxant tone. Perfusion 
of the heart with the adenosine antagonists would effectively cause vasoconstriction 
and therefore a decrease in the basal flow as the effects of the endogenous adenosine 
on the A2 a receptors would be antagonised.
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As well as decreasing the basal flow through the heart, perfusion of L-NAME, 8 -SPT 
and PD 115,199 also significantly reduced the increase in flow induced by SNP (lOOji 
M, p < 0.05, Students't' test). These results were rather unexpected as SNP is 
considered to be an endothelium-independent vasodilator and therefore its responses 
should not be affected by the presence of L-NAME. Indeed, the concentration 
response curves for SNP in the presence and absence of L-NAME in unpaired hearts 
were not significantly different, although a slight rightward shift in the SNP 
concentration response curve was produced by L-NAME. The effects of SNP are not 
mediated by adenosine receptors but by conversion to nitric oxide and direct activation 
of guanylate cyclase in the vascular smooth muscle, so the adenosine antagonists 
should also have no effect on the SNP response. The agonist, phenylephrine 
(lOOnM) was used to investigate the effect of vasoconstriction on the basal flow 
through the heart and the increases in flow induced by the agonists. PE not only 
produced vasoconstriction of the coronary arteries indicated by a 31% decrease in the 
basal flow through the heart, but also caused a 64% reduction in the SNP induced 
increase in flow. It is possible that the vasoconstriction caused by PE may be 
responsible for physiological antagonism of the SNP response and hence the decrease 
in the vasodilation induced by this agonist. If this is the case, as L-NAME, 8 -SPT and 
PD 115,199 effectively caused vasoconstriction by removing the basal relaxant tone of 
the coronary vessels, the reduction in the SNP induced increase in flow produced by 
these inhibitors could also be explained by physiological antagonism. The hearts were 
also perfused with Krebs solution for 20 minutes to ascertain whether the basal and 
agonist induced flows were affected by the time taken to perfuse the hearts with the 
inhibitors, i.e. whether there was a time dependent effect on the vasodilator responses. 
Over the 20 minute perfusion time the basal flow through the heart was not affected, 
but the increase in flow induced by SNP was reduced by 33%. This decrease in the 
SNP response can not be due to physiological antagonism as there was no change in 
the basal flow and therefore no vasoconstriction of the coronary vessels. Therefore it
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is likely that this 33% decrease in the SNP induced increase in flow is a time dependent 
reduction. Consequently, it is possible that the decrease in the SNP response by L- 
NAME, 8 -SPT and PD 115,199 could also be partly due to a time dependent 
(approximately 33%) decrease as well as the influence of physiological antagonism.
A time dependent reduction in vasodilator responses would also explain the signiflcant 
reduction (28%) in the NECA induced increase in flow seen over a 20 minute 
perfusion of the heart with Krebs solution. Physiological antagonism due to 
vasoconstriction could also explain the signiflcant reduction in the increase in flow 
induced by NECA produced by L-NAME, 8 -SPT and PE (p < 0.05 and p < 0.1, 
Students t ' test). The concentration response curves of NECA and CGS 21680 on 
separate hearts were shifted to the right by the presence of L-NAME suggesting these 
agonist responses were only partially endothelium-dependent. However when using 
paired responses in the same heart, L-NAME caused a 3.5mls/min (6 8 %) reduction in 
the increase in flow induced by NECA (3pM) which can be attributed to physiological 
antagonism (Table 4). The true response of NECA in the presence of L-NAME would 
therefore be approximately 3.5mls/min (6 8 %) higher than shown by the concentration 
response curve. If the position of the NECA concentration response curve in the 
presence of L-NAME was increased at each concentration by 3.5mls/min it would 
become very similar to the concentration response curve produced in the absence of L- 
NAME. This would imply that the vasodilation of the coronary arteries induced by 
NECA is endothelium-independent. If this argument is repeated with the other 
adenosine agonists it can be seen that in each case the concentration response curves in 
the presence and absence of L-NAME become remarkably similar suggesting that all of 
these adenosine agonist responses are probably endothelium-independent and are 
mediated by adenosine receptors present on the vascular smooth muscle of the 
coronary arteries. The apparent reduction in the agonist responses by L-NAME can in 
each case be entirely explained by the effects of time and physiological antagonism.
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The reduction of the NECA response caused by 8 -SPT (99.6%) was much greater than 
the reduction in NECA response in the presence of L-NAME and Krebs solution (6 8 % 
and 28% decrease in flow respectively). Using a one-way ANOVA analysis followed 
by a Dunnetts multiple comparisons post-hoc test the reduction in the NECA induced 
vasodilation caused by 8 -SPT was compared to the reduction seen with perfusion of L- 
NAME and Krebs solution. A signiflcant difference (p < 0.05) was seen between these 
values indicating that the reduction in the NECA induced increase in flow caused by 8 - 
SPT was probably due to a combination of a time dependent reduction in response and 
physiological antagonism, but also due to antagonism of the adenosine receptors. This 
would imply that the inhibition of the adenosine agonist concentration response curves 
by 8 -SPT seen earlier in this study was probably a true indication of the effect of 8 - 
SPT. However, 8 -SPT and L-NAME caused approximately the same decrease in the 
basal flow (28% and 24% respectively) and therefore a similar degree of physiological 
antagonism would be expected. As the NECA induced increase in flow was decreased 
by 6 8 % (3.5mls/min) by L-NAME due to physiological antagonism, a similar reduction 
in the NECA induced response by 8 -SPT would also be expected due to the 
physiological antagonism. If this is the case, to compensate for the physiological 
antagonism an addition of approximately 3.5mls/min (6 8 %) to each concentration of 
the response curves of the adenosine agonists in the presence of 8 -SPT would alter the 
position of these curves. Hence, 8 -SPT would cause an inhibition of the adenosine 
agonist responses rather than the abolition of the agonist responses that was observed.
Perfusion of the heart with PD 115,199 (30nM) only decreased the NECA induced 
increase in flow by Iml/min (19%, Table 4). Again if this decrease is attributed to 
physiological antagonism of the NECA response due to vasoconstriction of the 
coronary vessels by PD 115,199 the true response of NECA in the presence of PD
115,199 is probably Iml/min higher than shown by the concentration response curve.
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Increasing each concentration of the response curve for NECA in the presence of PD
115,199 by Iml/min makes this curve very similar the concentration response curve in 
the absence of the antagonist. This suggests that PD 115,119 actually had no effect on 
the vasodilation induced by NECA. As PD 115,199 is considered to be selective for 
the A2a receptor this suggests that NECA induced vasodilation is not mediated via the 
A2 a receptor. In contrast a lower concentration of PD 115,199 (lOnM) virtually 
abolished the increase in flow induced by CGS 21680. Taking into consideration the 
apparent vasoconstrictor effect of PD 115,199 shown by the decrease in basal flow, 
this abolition of the CGS 21680 response cannot be explained entirely by physiological 
antagonism and a time dependent reduction in response, but is probably also due to 
antagonism of the A2  ^receptors. It was suggested earlier in this study that the greater 
maximal response achieved by NECA compared to CGS 21680 could be explained by 
a combination of both A2 a and A2y receptors in the coronary vessels. As the A2 a 
selective antagonist PD 115,199 inhibits the CGS 21680 induced increase in flow but 
does not inhibit the NECA induced increase in flow, this supports the suggestion that 
CGS 21680 is acting via A2  ^ receptors whilst NECA is acting via A213 receptors to 
produce vasodilation of the coronary arteries.
As well as reducing the basal flow and the increases in flow induced by the agonists, 
perfusion of the heart with L-NAME also decreased the force of contraction of the 
heart. This action is probably a consequence of the decrease in the basal flow through 
the heart induced by L-NAME. The decrease in flow would lead to an insufficient 
perfiision and oxygenation of the heart and consequently a decrease in the ability of the 
heart muscle to contract due to hypoxia and ischaemia. To establish whether the 
converse was also true, the effect of SNP on the heart was also investigated. Perfusion 
of the heart with SNP not only caused an increase in flow through the heart but also 
caused an increase in the force and rate of contraction of the heart. However, SNP did 
not have any effect on the isolated atria whereas isoprenaline significantly increased
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both the rate and force of contraction of the atria, (p < 0.05, Students't' test). As 
SNP did not have a positive chronotropic or inotropic effect on the atria it is unlikely 
that the increase in force and rate of contraction of the isolated heart induced by SNP 
was due to a direct positive chronotropic or inotropic effect. Instead the effect of SNP 
on the rate and force of the heart was probably an indirect consequence of the 
increases in flow induced by SNP. This would result in the opposite effect to L- 
NAME, allowing greater perfiision and oxygenation of the heart enabling it to perform 
better so an increase in the force and rate of contraction could be achieved. Nitric 
oxide has recently been shown to act as a negative inotrope in cardiac muscle (Shah 
and Lewis, 1993; Brady et al., 1993; Schülz and Triggle, 1994). Therefore SNP, a 
nitric oxide donor would be expected to have a negative inotropic effect on the heart 
whereas L-NAME an nitric oxide synthase inhibitor would be expected to have the 
opposite effect and act as a positive inotrope. However it is clear from our study, that 
L-NAME and SNP have negative and positive inotropic actions respectively. 
Therefore it is unlikely that L-NAME and SNP are producing direct effects on the 
heart as the changes in the force of contraction of the heart produced by these 
compounds in this study are opposite to the effects which would be expected. 
Therefore in this study it appears that L-NAME or SNP produced changes in the force 
and rate of contraction of the heart through indirect effects via changes in vessel tone 
and subsequent changes in flow rate through the heart.
In conclusion, the adenosine agonists produced an increase in flow through the isolated 
heart indicating vasodilation of the coronary arteries. The agonist potency order 
produced in the isolated heart would suggest that this response was mediated by A2  
receptors, although the high potency of the A2 a selective agonist CGS 21680 would 
suggest that these receptors are probably of the A2 a receptor subtype. Whilst carrying 
out experiments with the nitric oxide synthase inhibitor L-NAME and the adenosine 
antagonists 8 -SPT and PD 115,199 it became apparent that other factors such as
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decreases in basal flow and changes in force of contraction of the heart were 
influencing the vasodilator responses produced by the adenosine agonists. L-NAME, 
8 -SPT and PD 115,199 produced decreases in the basal flow through the heart 
indicating that these inhibitors induced vasoconstriction, which led to physiological 
antagonism of agonist responses and hence a reduction in the vasodilation achieved by 
these agonists. In addition to the physiological antagonism a time dependent reduction 
in the agonist responses also had to be considered when interpreting the agonist 
induced increases in flow in the presence and absence of the inhibitors. In the isolated 
heart the non-selective antagonist 8 -SPT inhibited the increases in flow induced by the 
adenosine agonists conflrming the presence of P^ receptors in the coronary vessels and 
also ruling out the involvement of xanthine-resistant responses and A3 receptors in 
coronary vasodilation. After taking into consideration the physiological antagonism 
caused by PD 115,199, it was found that although PD 115,199 inhibited the increases 
in flow induced by CGS 21680 it had no effect on the increases in flow induced by 
NECA. This suggests that CGS 21680 is acting via A2  ^receptors to mediate coronary 
vasodilation whereas NECA is not acting via A2 g receptors but is possibly via A21, 
receptors to mediate this response. L-NAME also caused physiological antagonism of 
the increases in flow induced by the agonists by causing vasoconstriction of the 
coronary vessels. When this was taken into consideration it was found that L-NAME 
had no effect on the increases in flow induced by the adenosine agonists implying that 
these responses were endothelium-independent and were mediated via the vascular 
smooth muscle. In addition to causing decreases in the basal flow and the agonist 
induced increases in flow, L-NAME also caused a decrease in the force of contraction 
of the heart. In contrast, SNP caused an increase in the force and also the rate of 
contraction of the heart although it did not have any effect on the isolated atria. It is 
likely that the responses induced by L-NAME and SNP are not direct effects but are 
due to the changes in the vessel tone and subsequent changes in the flow rate through 
the heart caused by these compounds.
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4.3. CONCLUSION
In this study the presence of adenosine receptors on the isolated rat thoracic aorta and 
the rat coronary arteries, studied using the Langendorff isolated heart preparation, 
have been confirmed. Adenosine and some of its analogues such as NECA, CGS 
21680, CPA and APNEA induce vasodilations of these vessels producing agonist 
potency orders which are indicative of the presence of A2  receptors on these tissues. 
Due to the high potency of the A2 a selective agonist CGS 21680 A2 a receptors are 
likely to be present on both the rat aorta and coronary arteries. However, the maximal 
response achieved by CGS 21680 in the thoracic aorta was only 6 6 % of the NECA 
maximal response, which led to the conclusion that although NECA is acting as a full 
agonist on the A2  ^receptors present on the aorta CGS 21680 is only acting as a partial 
agonist achieving a smaller maximum value than that obtained by NECA. The 
endogenous nucleoside MTA acted as very weak agonist inducing relaxations of the 
thoracic aorta only at very high concentrations. This response was not inhibited by the 
non selective antagonist 8 -SPT suggesting that MTA does not act via the A2 a 
receptors present on the aorta but on another site on the aorta which is resistant to 
blockade by 8 -SPT. However, MTA also appears to act as an antagonist on the A2 a 
receptors on the rat thoracic aorta inhibiting the responses induced by the adenosine 
agonists with a potency similar to that of 8 -SPT.
MTA, when used as an antagonist, the non selective antagonist 8 -SPT and the A2  ^
selective antagonist PD 115,199 all inhibited the relaxations of the rat thoracic aorta 
induced by the adenosine agonists. However in the presence of these antagonists 
NECA was inhibited to a greater extent than the other agonists. It is likely that all of 
the adenosine agonists, with the exception of MTA, are acting on the A2 a receptors 
present on the rat aorta. However, as CGS 21680, CPA and adenosine were inhibited
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to a lesser extent they may also be acting on another site on the aorta to mediate 
vasodilation. This may also be the site which mediates the weak reponses induced by 
MTA. The smaller dose-ratios produced by 8 -SPT and PD 115,199 using these 
agonists could be explained by agonist stimulation of this second site which displays 
some resistance to blockade by the adenosine antagonists. In the presence of 8 -SPT, 
MTA or PD 115,199 the maximal response produced by CGS 21680 increased so that 
CGS 21680 achieved a similar maximal response to that produced by NECA. This 
suggests that although CGS 21680 acts as a partial agonist on the A2 a receptors of the 
aorta, in the presence of these antagonists, CGS 21680 appears to be a full agonist 
activating a second site at which it is able to achieve a higher maximum value.
These unusual findings could be explained by the presence of other adenosine 
receptors present on the thoracic aorta. However, using DPCPX at an A% selective 
concentration (InM) no evidence could be found for the presence of relaxant Aj 
receptors on this vessel. Also the different degrees of antagonism and xanthine- 
resistant effects of MTA could not be explained by the presence of A3 receptors as the 
agonist potency order produced in the presence of 8 -SPT and MTA in this study is 
different to the agonist potency order which would be expected in the presence of A3 
receptors.
Initially in the isolated rat heart the effects of the adenosine antagonists and other 
inhibitors such as the nitric oxide synthase inhibitor L-NAME on the agonist 
concentration response curves were carried out in a similar fashion to the rat aorta, 
using unpaired isolated hearts. However, it emerged that several problems arose with 
this protocol as the interpretation of the agonist induced changes in flow became 
difficult due to other effects such as a decrease in basal flow caused by the antagonists 
and L-NAME. Experiments were therefore carried out so that the effect of the 
inhibitors on the basal flow and the increases in flow induced by SNP and NECA could
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be established on individual hearts in a paired manner. This made the interpretation of 
the changes in flow rate easier and in some cases altered the conclusions made about 
these results. It was found that L-NAME, phenylephrine and the adenosine 
antagonists 8 -SPT and PD 115,199 all decreased the basal flow through the heart 
indicating vasoconstriction of the coronary vessels. As all of these compounds also 
reduced the increase in flow induced by NECA and SNP, it was proposed that the 
reductions in vasodilation induced by these agonists were due to physiological 
antagonism caused by the vasoconstriction produced by the inhibitors. Also perfusion 
of the heart with Krebs solution for the same amount of time required for perfusion of 
the inhibitors (20 minutes) caused a decrease in the SNP and NECA induced 
responses. This could not be attributed to physiological antagonism as no change in 
basal flow was observed, hence this was due to a time dependent reduction in the 
agonist induced responses. Therefore it became apparent that the interpretation of the 
changes in flow produced by the adenosine agonists and the effects of the antagonists 
and inhibitors on these changes in flow also had to take into account a time dependent 
reduction in responses as well as physiological antagonism which could oppose the 
vasodilator responses produced by the agonists.
In the isolated rat heart the non selective antagonist 8 -SPT abolished the increases in 
flow induced by all of the adenosine agonists. This confirmed that the vasodilation of 
the coronary vessels is mediated by Pj purinoceptors, and also suggested that 
xanthine-resistant responses and A3 receptors are probably not involved in this 
response. As mentioned previously, when considering the effect of 8 -SPT on the 
agonist induced responses the physiological antagonism due to the decrease in the 
basal flow caused by 8 -SPT should also be taken into account. If the possible effect of 
physiological antagonism is added onto the concentration responses curves of the 
adenosine agonists in the presence of 8 -SPT it can be seen that this antagonist probably 
inhibits the effects of the agonists rather than abolishing them.
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In the isolated heart PD 115,199 (30nM) inhibited the NECA response shifting the 
concentration response curve slightly to the right whilst a lower concentration of PD
115.199 (lOnM) virtually abolished the CGS 21680 induced increase in flow. This 
suggests that both of these agonists act via the A2 a receptors present on the coronary 
arteries, although this would not explain the different antagonistic effects of PD
115.199 on NECA and CGS 21680. The initial explanation for the different effects of 
PD 115,199 was that it was acting as a non-competitive /irreversible antagonist. It has 
been suggested that NECA is a full agonist and CGS 21680 is a partial agonist on the 
A2 a receptors on the coronary arteries. In this case, the effect of such an antagonist on 
their concentration response curves would be different, the concentration response 
curve for NECA being shifted to the right in a parallel manner whilst the concentration 
response curve for CGS 21680 would be shifted rightward in a non parallel manner 
with a reduced maximum value. However this explanation is unlikely as no evidence 
for non-competitive effects were seen for PD 115,199 in binding at A2  ^ receptors in 
the rat striatum. Moreover, because PD 115,199 caused vasoconstriction of the 
coronary vessels indicated by the decrease in basal flow, some of the inhibitory effect 
of PD 115,199 on the agonist induced responses was probably due to physiological 
antagonism. When the effect of physiological antagonism was added to the NECA 
concentration response curve in the presence of PD 115,199 it was found that this 
curve became very similar to the curve in the absence of the antagonist. Unlike the 
previous interpretation this suggests that NECA is not acting on A2 a receptors on the 
coronary arteries. The different maximal responses produced by NECA and CGS 
21680 in the isolated heart could instead have been due to the presence of two 
receptors with different maximal values, for example the A2  ^ and A2y receptors. 
Therefore it is possible that the NECA induced response is mediated via A2y receptors 
which may be present on the coronary arteries. In contrast, the virtual abolition of the 
CGS 21680 induced response by PD 115,199 was probably due to a combination of a
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time dependent reduction in response, physiological antagonism as well as antagonism 
of the A2 a receptor mediated vasodilation induced by CGS 21680.
The relaxations induced by the adenosine agonists in the isolated rat aorta were 
virtually abolished by the mechanical removal of the endothelium suggesting these 
responses were endothelium-dependent. As the agonist responses were also virtually 
abolished by the presence of the nitric oxide synthase inhibitor L-NAME this also 
implies that these responses occur through an endothelium-dependent mechanism 
involving the nitric oxide pathway. In the rat isolated heart the situation was slightly 
more complex. Initially it was found that L-NAME abolished the response induced by 
CPA and adenosine, probably due to their low potency in the absence of the inhibitor, 
and also inhibited the responses induced by NECA and CGS 21680 shifting their 
concentration response curves to the right. This would imply that the agonist induced 
responses were only partially endothelium-dependent and were mediated via adenosine 
receptors present on both the endothelium and the vascular smooth muscle. However, 
L-NAME was found to cause vasoconstriction indicated by the reduction in the basal 
flow through the heart, and this vasoconstriction caused a physiological antagonism 
and therefore a reduction of the vasodilator responses produced by the adenosine 
agonists. When the reduction in response due to the physiological antagonism was 
added on to the agonist concentration response curves in the presence of L-NAME it 
was found that the concentration response curves in the presence and absence of the 
inhibitor were remarkably similar. This would imply that L-NAME has no effect on 
the responses induced by the adenosine agonists, and that, unlike the rat thoracic aorta, 
the vasodilations induced by the adenosine agonists are endothelium independent and 
do not involve the nitric oxide pathway.
As well as decreasing the basal flow and the agonist induced flows through the heart. 
L-NAME also decreased the force of contraction of the heart. SNP produced the
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opposite effect and increased not only the force but also the rate of contraction of the 
heart although it did not affect the force or rate of contraction of isolated atria. These 
actions of L-NAME and SNP were therefore probably not direct effects but 
consequences of the changes in the flow rate induced by these compounds. For 
example, the decrease in basal flow caused by L-NAME would lead to an insufficient 
perfusion and oxygenation of the heart and consequently a decrease in the hearts ability 
to contract to its fiill potential due to hypoxia and ischaemia. Conversely, SNP caused 
an increase in flow through the heart and hence better perfusion and oxygenation of the 
heart and therefore the heart was able to perform better so an increase in the force and 
rate of contraction of the heart was observed.
In conclusion, the characterisation of adenosine receptors present on the isolated rat 
thoracic aorta and the rat coronary arteries, studied using the Langendorff isolated 
heart technique has been carried out. On the rat thoracic aorta the relaxations induced 
by the adenosine agonists were mediated via A2  ^receptors, with the exception of the 
relaxations induced by MTA which were not inhibited by 8 -SPT. However, NECA 
was inhibitied to a greater extent than the other agonists by 8 -SPT, MTA and PD
115,199 indicating that that the relaxations induced by the other agonists were 
mediated by A2  ^ receptors but also by another site which displays some resistance to 
blockade by xanthines. The differing degrees of antagonism and xanthine-resistant 
responses do not appear to involve Aj or A3 receptors. The relaxations induced by the 
agonists in the rat aorta were abolished by removal of the endothelium and inhibition 
by L-NAME therefore these responses are endothelium-dependent and involve the 
nitric oxide pathway. In the rat coronary arteries the adenosine agonists induced 
increases in flow through the heart indicating vasodilation of these vessels. L-NAME, 
8 -SPT and PD 115,199 caused vasoconstriction of the coronary arteries which led to 
physiological antagonism of the increases in flow induced by the agonists and hence a 
reduction in the vasodilation induced by these agonists. This physiological antagonism
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and also a time dependent reduction in the agonist responses had to be taken into 
consideration when interpretation of the results was carried out. It appears that the 
adenosine agonists mediate vasodilation of the coronary arteries via A2  receptors, 
although due to its high potency it is likely that CGS 21680 is acting via A2 a receptors. 
However as the increase in flow induced by NECA was not inhibited by the A2  ^
selective antagonist PD 115,199 it appears that NECA is not acting via A2 a receptors 
but possibly via A213 receptors to induce coronary vasodilation. When the effect of 
physiological antagonism was taken into consideration, L-NAME did not have any 
effect on the increases in flow induced by the adenosine agonists, so therefore these 
responses were endothelium-independent and are mediated by the vascular smooth 
muscle of the coronary arteries.
Characterisation of the purinoceptors present on the rat thoracic aorta and the 
coronary arteries is based on agonist potency orders, the potency of the A2 a selective 
agonist CGS 21680 and the use of selective antagonists such as PD 115,199. 
Classification of the receptors on these and other tissues would become easier and 
more reliable by development of more selective agonists and antagonists, especially for 
the A2b and A3 receptors. The use of selective A3 antagonists in the rat thoracic aorta 
would confirm that A3 receptors were not involved in the relaxation of the rat aorta. 
A3 receptors antagonists such as BW-A522 and BW-A1433 have recently been 
developed and could be used in the rat aorta to eliminate the presence of A3 receptors, 
although they are not selective for the A3 receptor versus the Aj and A2 a receptors 
(Kim et a l, 1994b). As the increases in flow induced by NECA in the isolated heart 
were not mediated via A2  ^receptors it was suggested that this response was mediated 
via A215 receptors. With selective A2y receptor agonists and antagonists it would be 
possible to establish whether NECA does indeed mediate coronary vasodilation via 
these receptors. It was found in the study on the isolated heart that interpretation of 
the increases in flow induced by the agonists were complicated by physiological
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antagonism due to vasoconstriction produced by the adenosine antagonists. Therefore 
when using adenosine antagonists in the isolated heart the effect of physiological 
antagonism on the agonist responses must be considered. The contribution of the 
physiological antagonism produced by PD 115,199 on the increase in flow induced by 
CGS 21680 should be established to ascertain the true vasodilator response produced 
by CGS 21680 in the presence of this antagonist. PD 115,199 could also be used to 
investigate whether the responses induced by the other agonists used in this study, 
CPA and adenosine were also mediated via A2  ^receptors, like CGS 21680, or possibly 
via A213 receptors, like NECA. The unusual results in the rat thoracic aorta using 
MTA prompt further investigation of the effects of this endogenous nucleoside. It has 
been reported that MTA acts as a xanthine-sensitive weak or partial agonist on A2  ^
receptors on rat PC 12 cells and as an antagonist on A215 receptors on human fibroblast 
and neuroblastoma cells (Daly and Padgett, 1992; Bruns et ah, 1986; Munshi et al., 
1988). However, in this study on the rat aorta MTA acted as a weak agonist on a 
xanthine-resistant site and an antagonist on A2 a receptors present on the aorta. It 
would be interesting to ascertain the actions of MTA on a wider range of tissues and 
especially other isolated blood vessels to establish whether MTA has similar actions to 
those seen on the rat aorta. It was noted during the discussion that the guinea-pig 
trachea and the rat aorta appear to be very similar with respect to the differing degrees 
of antagonism of the agonist responses and the weak xanthine-resistant effects of 
MTA. It is possible that the xanthine-resistant site on the aorta and the guinea-pig 
trachea may be identical, although in both cases further investigation of this site would 
be needed.
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